FORM 10-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
(Mark One)
X Annual report pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934 (Fee Required)
For the fiscal year ended December 31, 1999 or
___Transition report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 (No Fee Required)
For the transition period from ___________________ to__________________
Commission File Number 0-12516
Dynamic Healthcare Technologies, Inc.
(Exact name of registrant as specified in its charter)
Florida 59-3389871
(State of Incorporation) (IRS E.I.N.)
615 Crescent Executive Court, Fifth Floor, Lake Mary, Florida 32746
(Address of principal executive offices) (ZIP Code)
(407) 333-5300
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: Common Stock
(Title of Class)
Indicate by checkmark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes X No ____
The aggregate market value of the voting stock held by non-affiliates, based
on the average bid and asked prices as of March 2, 2000, was $35,371,000. A
total of 13,803,277 shares of the Company's common stock were held by
persons and entities believed to be non-affiliated on March 2, 2000, and the
closing bid and ask prices of the Company's common stock on this date were
$2.500 and $2.625, respectively.
As of March 2, 2000, there were 18,866,693 shares outstanding of the
issuer's only class of common stock.
This report consists of fifty-four (54) pages.
The index to exhibits appears on page twenty (20).
Documents Incorporated by Reference
(1) Portions of the definitive proxy statement for the Company's 1999
Annual Meeting of Shareholders, to be filed within 120 days from the end of
the Company's fiscal year covered by this report, pursuant to General
Instruction G(3) to Form 10-K.
1
FORM 10-K
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
PART I
Item 1. Business
General
Dynamic Healthcare Technologies, Inc. ("Dynamic" or the "Company") is a
provider of Internet and image-, voice-, and web-enabled information systems
for clinical services departments and facilities. The Company's product line
is a suite of solutions for anatomic pathology, radiology, laboratory,
surgical services and health information management. In 1999, the Company
launched a strategic initiative to move into the e-Health arena by converging
its traditional clinical applications with emerging Internet technologies.
The resulting e-Health solutions enable physicians, clinicians, and
departmental staff both inside and outside the healthcare facility, to use
Dynamic's systems over the Internet, thereby extending their reach to
remote hospitals, outreach service locations, reference labs, physician
offices and homes. An e-Health solution set positions the Company to
participate in the e-Health business to business (B2B) marketplace. The
Company is also moving forward with plans to package and deliver its software
and services on a "fee-per-use" basis through an Application Solution
Provider (ASP) model.
Dynamic's information systems contribute to higher quality and more cost-
effective delivery of care and make it possible to have access to information
"anytime/anywhere." Dynamic is headquartered in the greater Orlando area and
has a key operations and development center near Boston. The Company
provides support for all of its systems and also offers integration and other
consulting services.
Dynamic currently serves more than 650 customers, most located in the United
States. Key customers include Massachusetts General Hospital, Methodist
Hospital of Memphis, Orlando Regional Health System, University of North
Carolina Hospitals, University of Pittsburgh Medical Center Health System,
University of Illinois at Chicago Medical Center, Memorial Sloan-Kettering
Cancer Center, Advocate Health Care, Borgess Health Alliance, The Mayo Clinic
and Medical College of Virginia.
The Company was originally incorporated in California in 1977, reincorporated
in Nebraska in 1982 and subsequently reincorporated in Florida in 1996. The
Company's executive offices are located at 615 Crescent Executive Court,
Fifth Floor, Lake Mary, Florida 32746. Its telephone number is (407) 333-
5300 and its World Wide Web address is http://www.dht.com.
Industry
The healthcare industry continues to undergo rapid and significant change.
Cost containment pressures, industry consolidation, the increasing impact of
managed care, rising standards of healthcare quality, the shift from
inpatient to outpatient care settings, competition amongst healthcare
providers, increasing involvement of patients in their healthcare delivery
process, and the demand for instant access to information on the part of
physicians, patients and payers represent fundamental trends in today's
healthcare operating environment. Although healthcare has been slower than
other industries to recognize the value of information technology, healthcare
providers recognize that the key to effective cost control and quality
management lies in the collection, availability and analysis of medical
record information to assess treatment patterns, resource utilization and
outcomes.
While healthcare providers agree that they must invest in information systems
technology to increase productivity and efficiency, measure and manage costs,
and improve the quality of the services they deliver, much of their attention
during 1999 was directed toward assuring Y2K compliance of their existing
information systems. The 1999 Annual Healthcare Information Management and
Systems Society ("HIMSS") Leadership Study indicated that 39% of the 1100+
survey respondents sited Y2K compliance as the highest priority for their
organizations over the next 12 months. During this time period, as expected,
these efforts did distract attention and divert some capital funds that might
otherwise have been used for new information systems. It is expected that
delays resulting from those efforts will continue, to a lesser degree,
through the first half of 2000.
As Y2K compliance efforts subside, another major challenge confronts the
healthcare industry: The Department of Health and Human Services (HHS) has
issued proposed regulations specifying the confidentiality requirements for
electronically captured personal health information mandated by the Health
Insurance Portability and Accountability Act ("HIPAA"). These regulations,
projected to be finalized by mid-year, are expected to go into effect in
early 2002. The entire healthcare community - providers, payers, software
developers, consultants and users - will devote tremendous efforts over the
next two (2) years implementing the final HIPAA confidentiality regulations
(the "Regulation"). HHS has estimated that the cost of meeting HIPAA
2
compliance will exceed $3.8 billion. It should be noted that the Company
employs a full time regulatory consultant whose duties include monitoring and
advising management of the applicable sections of HIPAA that will apply to
the company's business.
It is clear that the emergence of the Internet as the medium of choice for
global information access and communication offers significant potential to
meet these rapidly increasing demands for information by all participants in
the delivery of healthcare. The growth rate of Internet users seeking health-
related information is expected to outpace the rapid growth of total Internet
users as far out as consulting analysts are currently willing to project.
Given its expanded market reach and significantly lower operating costs, the
Internet has become a mission-critical competitive technology for all
software companies. The Internet has the ability to transform the $1.2
trillion healthcare sector from a cottage industry that gets by on incomplete
and inaccurate data to one that is fueled by increased information flow.
This will be accomplished by connecting all participants in the delivery of
health services and empowering consumers and purchasers of healthcare to make
better decisions. International Data Corporation (IDC) indicates that
capital spending on "Web-enablement" will grow from $305 billion in 1999 to
$1.5 trillion by 2003. Forrester Research anticipates that business-to-
business (B2B) e-Commerce will reach $1 trillion by 2003.
Products and Services
Dynamic Healthcare Technologies uses the power of technology to improve
patient care and lower costs by connecting people with information. The
Company's DynamicVision(R) suite of clinical information systems includes
radiology, anatomic pathology, health information management, laboratory and
surgical services. The Company's e-Health solutions enable physicians,
clinicians, and departmental staff both inside and outside the healthcare
facility, to use Dynamic's systems over the Internet, thereby extending
their reach to remote hospitals, outreach service locations, reference labs,
physician offices and homes. Using these solutions, health professionals
have access to the clinical information they need to make decisions and
manage patient care, anytime, anywhere.
Products Type of
Generally Available Solution Product Line
I. e-Health Solutions All product lines
e-Premier LIS Web-enabled e-PremierTM is a web-enabled version of
Laboratory the Premier Series LIS and a component
Information of the Company's e- business
System (LIS) initiative. Announced in Q1, 2000, e-
Premier enables laboratory and clinical
staff, to use the LIS over the
Internet/Intranet, extending the reach
of the laboratory to remote hospitals,
outreach service locations, reference
labs, physician offices and homes.
WebSight for Radiology Teleradiology WebSight for Radiology is a browser
-based teleradiology system that
provides radiologists and physicians
with access to images and information
anytime/anywhere.
WebSight for Pathology Telepathology WebSight for Pathology is a browser-
based information system for
communicating pathology reports over the
Internet to remote facilities and
clinicians.
Remote Transcription Radiology With this capability, remote
transcriptions are able to access the
Company's RadPlus radiology information
system (RIS) over the Internet to
transcribe, approve and disseminate
radiology reports to referring
physicians. This web-based connectivity
to RadPlus gives staff
"anytime/anywhere" access to integrated
radiology result transcription and
report features to reduce turnaround
time in the patient report completion
process.
3
Products Type of
Generally Available Solution Product Line
Dynamic e-Shop e-Commerce e-Shop is a business-to-business
e-commerce initiative that gives
customers access to the Company's
catalog of selected products and
services and enables them to make
purchases over the Internet.
II. Radiology DynamicVision for Radiology
Dynamic RadPlus(TM) Radiology RadPlus is a voice- and
Information System image-enabled client/server
radiology information system that
manages clerical and
administrative functions for the
radiology department. Application
areas include scheduling, patient
tracking, film tracking and
department reporting.
Maxifile(R) Radiology Maxifile is a first generation
Information System MUMPS-based radiology information
system that manages clerical and
administrative functions for the
radiology department. Application
areas include scheduling, patient
tracking, film tracking and
reporting. The Company is
aggressively promoting customer
migrations from Maxifile to
Dynamic RadPlus.
Dynamic PACSPlus(TM) PACS PACSPlus is an information-enabled
picture archiving and
communication system (PACS) that
integrates information from the
radiology information system with
images and provides access
to the patient's complete
radiology history via local and
remote PACSPlus workstations. The
Company received FDA 510K
clearance to market Dynamic
PACSPlus in December 1998.
Dynamic Optima(R) Mammography Optima is an integral component
Management of Dynamic RadPlus. It
computerizes patient management,
reporting and regulatory
requirements related to
mammography services. Through an
OEM agreement, the Company
markets the Penrad system under
the name Dynamic Optima. Penrad
Inc. is a Dynamic business
partner.
Dynamic Talk Continuous Talk is an integrated component
Speech Recognition of RadPlus and gives radiologists
the option of dictating and
editing their own diagnostic
reports using continuous speech
recognition technology, thus
reducing transcription costs and
delays in communicating reports to
physicians.
WebSight for Radiology Teleradiology WebSight for Radiology is a
browser-based teleradiology system
that provides radiologists and
physicians with access to images
and information anytime/anywhere.
III. Anatomic Pathology DynamicVision for Pathology
Dynamic CoPathPlus(TM) Anatomic CoPathPlus is a voice and
Pathology System image-enabled client/server
pathology information system
that automates specimen
accessioning and case
dictation, produces patient and
management reports, and
provides SNOMED and natural
language retrieval of
diagnoses.
CoPath M Anatomic CoPath M is a first generation,
Pathology System MUMPS-based pathology
information system that
automates specimen accessioning
and case dictation, produces
patient and management reports,
and provides SNOMED and natural
language retrieval of
diagnoses. The Company is
aggressively promoting customer
migrations from CoPath M to
CoPathPlus.
4
Products Type of
Generally Available Solution Product Line
Dynamic PICSPlus(TM) Image PICSPlus is an integrated
Management System component of Dynamic
CoPathPlus. It captures stores
and communicates high-resolution
digital microscope and gross
images of pathology specimens.
The foundation of PICSPlus is
the AutoCyte Image Management
System, (AIMS), a product of
TriPath Imaging, Inc.(formerly
AutoCyte, Inc.). The Company
has an exclusive North American
marketing agreement with TriPath
Imaging.
WebSight for Pathology Telepathology WebSight for Pathology is a
browser-based information system
for communicating pathology
reports over the Internet to
remote facilities and
clinicians.
Dynamic Talk Continuous Talk gives pathologists the
Speech Recognition option of dictating and
editing their own diagnostic
reports using continuous speech
recognition technology, thus
reducing transcription costs and
report delays.
IV. Clinical Laboratory DynamicVision for Laboratory
Premier Series Laboratory Premier Series manages clerical
Information and administrative functions in
System (LIS) the clinical laboratory,
including monitoring and
controlling specimens, ordering,
tracking and results reporting.
e-PremierTM Web-enabled e-Premier Laboratory Information
Laboratory System (LIS) is a web-enabled
Information System version of the Premier Series
(LIS) LIS and a component of the
Company's e-business initiative.
Announced in Q1, 2000, e-Premier
enables laboratory and clinical
staff to use the LIS over the
Internet, extending the reach of
the laboratory to remote
hospitals, outreach service
locations, reference labs,
physician offices and homes.
LabPro 2000 Laboratory LabPro 2000 is a first
Information System generation LIS that manages
(LIS) the clerical and administrative
functions in the clinical
laboratory, including monitoring
and controlling specimens,
ordering, tracking and
results reporting. The Company
is aggressively promoting
customer migrations from LabPro
to Premier Series and e-Premier.
V. Electronic DynamicVision for Health Information Management
Document Management
Dynamic RecordPlus(TM) Document Imaging RecordPlus is an enterprise-
and Workflow wide, electronic document
management system that provides
document imaging and workflow
management, chart completion,
and business process automation
for the health information
management department (medical
records), business office and
other document intensive
departments.
5
Products Type of
Generally Available Solution Product Line
VI. Surgical Services DynamicVision for Surgical Services
Dynamic SurgiPlus(TM) Perioperative SurgiPlus is a perioperative
Clinical clinical information system
Information System currently in development. The first
application, the Preoperative
Evaluation, comprises two
components: A) a Preoperative
Assessment module that captures and
stores pertinent patient
information, history
questionnaires, physical
examinations; and B) a Preoperative
Holding module that captures and
presents the documentation related
to final preparation of the patient
by nursing and anesthesia
personnel. Preoperative Assessment
is currently in live operation at
an Alpha site and Preoperative
Holding is scheduled for delivery
in Q2 2000.
DynamicVision for Radiology
The Company's radiology solution combines advanced client/server architecture
with web technology. Competitive advantage is gained by the close
relationship between the Radiology Information System (RIS) and the Picture
Archiving and Communication System (PACS). Information collected by the RIS
is available to the PACS, and images captured by the PACS are available to
the RIS. The result is an "image-enabled" RIS combined with an "information-
enabled" PACS. Primary markets for the Company's radiology solutions include
hospitals, clinics and independent diagnostic imaging centers.
Dynamic RadPlus is an image-enabled, client/server radiology information
system that includes scheduling, patient tracking, film tracking, remote
transcription, reporting, and management of all radiology functions. Using
RadPlus, facilities can easily adapt to change with the unique Dynamic
Customizer tool, which allows users to make screen modifications without the
expense and delays of reprogramming by the vendor. RadPlus is also voice-
enabled. Through the Dynamic Talk continuous speech recognition solution,
radiologists reduce or eliminate the costs and delays of transcription and
immediately deliver results simply by speaking, editing, and then approving
the reports on-line. As an alternative, remote transcriptionists have the
ability to access RadPlus over the Internet to transcribe, approve and
disseminate radiology reports to referring physicians. This web-based
connectivity to RadPlus provides "anytime/anywhere" access to integrated
radiology result transcription and report features to reduce turnaround time
in the patient report completion process.
The Dynamic Optima mammography management system, is an integral component
of RadPlus. It automates the reporting, patient management, and regulatory
requirements related to mammography services. Through an OEM agreement, the
Company markets the PenRad system under the name Dynamic Optima. PenRad Inc.
is a Dynamic business partner.
Dynamic PACSPlus is an information-enabled picture archiving and
communication system, (PACS) that integrates information from the RIS with
images - and provides access to this information from within the PACSPlus
system. Dynamic WebSight, a vital component of PACSPlus, is a web-based
teleradiology system that provides radiologists and physicians with access to
radiology images anytime/anywhere.
DynamicVision for Pathology
The Company's solution for anatomic pathology (A/P) is a scalable,
client/server solution that is enabled with advanced voice, imaging and web
capabilities.
Dynamic CoPathPlus is a client/server anatomic pathology system that
automates specimen accessioning and case dictation, produces patient and
management reports, and provides SNOMED and natural language retrieval of
diagnoses. CoPathPlus also enables facilities to adapt to change with
Dynamic Customizer, a tool set that allows user modification of specimen data
entry windows and report formats. CoPathPlus is image-enabled through
Dynamic PICSPlus, which captures high-resolution digital images of
microscopic and gross specimens and permanently stores these images
electronically with patient and diagnostic data. CoPathPlus is voice-enabled
with the Dynamic Talk continuous speech recognition solution, which expedites
the pathology dictation process and results in shorter turnaround time in
delivering patient reports to clinicians. WebSight for Pathology is an
advanced, web-based solution that enables the delivery of pathology reports
over the Internet to physicians and clinicians at remote locations.
6
DynamicVision for Laboratory
The Premier Series laboratory information system provides functionality for
specimen collection, testing, and result reporting. Premier Series supports
bar coding, instrument interfaces, paperless microbiology, multi-facility
management, and optical storage. Other features include quality assurance
workload recording, management reporting, and expert system capabilities.
Premier Series integrates with highly specialized blood bank information
systems, providing both transfusion and donor service software as well as
regulatory products. Premier Series complies with federal regulations and
assists laboratories deciding upon the appropriate and medically necessary
course of action in diagnosing and treating the patient.
e-Premier is the Company's web-enabled version the Premier Series LIS. A
component of the Company's e-Health initiative, e-Premier enables laboratory
and clinical staff, both inside and outside the hospital, to use the LIS over
the Internet, extending the reach of the laboratory to remote hospitals,
outreach service locations, reference labs, physician offices and homes.
Referring physicians and clinicians using any Internet-connected device can
have anytime/anywhere access to enter laboratory orders and review patients'
laboratory test results.
DynamicVision for Health Information Management
Dynamic RecordPlus provides document management and workflow capabilities for
the health information management department (medical records) as well as the
patient accounting and other document-intensive departments. It enables
health professionals to view patient records, result reports, and work list
assignments. Comprehensive workflow features automate existing work processes
for improved customer service and increased efficiency. RecordPlus also
handles analysis and assignment of chart deficiencies, electronic signature
of records, and release of information. For the patient accounting
department, RecordPlus provides document management and workflow solutions
to enhance the management and flow of accounting-related documents and tasks.
It enables accounting professionals to view financial records and work list
assignments and automates existing work processes for improved customer
service and increased efficiency. RecordPlus also handles management and
prioritization of billing claims, collections, and insurance verification.
DynamicVision for Surgical Services
SurgiPlus is a perioperative clinical information system currently in
development. The first application, Preoperative Evaluation, comprises two
components: A) a Preoperative Assessment module that captures and stores
pertinent patient information, history questionnaires, physical examinations;
and B) a Preoperative Holding module that captures and presents the
documentation related to final preparation of the patient by nursing and
anesthesia personnel. The Preoperative Assessment module is in live
operation and the Preoperative Holding module is in the final phase of
development and will be implemented in the first customer site in the near
future. Additional modules of SurgiPlus are in various stages of development
at this time. They include scheduling, inter-operative data recording, post-
operative care, 48-hour post anesthesia interview, pain management, report
generation, quality control and outcomes analysis.
Consulting, Systems Integration and other Services
The Company provides a full range of professional consulting services
including project management, implementation, planning, training and
education. The Company's technical services include network design,
implementation and support, custom software development, interfaces, and
modifications and systems integration. The Company provides support services
including 24-hour telephone support and software maintenance and
enhancements.
Research and Development
The Company's research and development program is designed to extend the
capabilities of existing products and develop new healthcare application
solutions. The Company believes that a substantial and sustained commitment
to product development is important to the long-term success of its business.
As of December 31, 1999, 53 employees were engaged in research and
development activities. During the years ended December 31, 1997, 1998 and
1999, the Company spent approximately $8,336,000, $8,064,000 and $6,806,000
respectively, on research and development. Research and development
expenditures have been directed toward Dynamic RadPlus(TM), PACSPlus(TM),
CoPathPlus(TM), RecordPlus(TM) and SurgiPlus(TM) product lines. The Company's
research and development benefits from customer input and user group forums.
7
Major Clients
The Company does not have a dependence on any single customer, the loss of
which would have a material adverse effect. The Company does generate
revenue almost exclusively through sales to the healthcare industry located
in the United States. Due to this concentration, substantially all
receivables of the Company are from healthcare institutions which may be
similarly affected by changes in economic, regulatory or other industry
related conditions. The Company currently has approximately 650 customers.
The majority of these customers are located within the United States.
Backlog
As of December 31, 1999 the Company has a combined backlog of approximately
$24.5 million. The Company had contracts for the delivery of systems and
services totaling approximately $9.8 million on December 31, 1999, compared
to $13.8 million on December 31, 1998. In addition, as of December 31, 1999
the Company had contracts for the delivery of software support services
billable at an annual rate of $14.7 million, compared to $14.2 million as of
December 31, 1998.
Strategic Relationships
The Company has entered into strategic relationships with several leading
technology developers to gain access to certain technologies that are
integrated into the Company's systems. In addition, through these strategic
relationships, the Company is able to cross-market its internally developed
or acquired technologies to customers of its business partners.
IBM - In 1997, the Company acquired IBM's Medical RecordsPlus enterprise
document imaging and management system. This AS/400 product is based on
IBM's ImagePlus/400 image processing system. The Company has also integrated
IBM's MedSpeak/Radiology(TM) solution into its RadPlus radiology information
system and MedSpeak/Pathology(TM) into its CoPathPlus anatomic pathology system
under the name Dynamic Talk. This expands the functionality of these two
solutions to include continuous speech recognition for direct dictation of
results, bypassing the need for transcription of diagnostic reports.
Continuous speech recognition allows radiologists and pathologists to dictate
at a normal rate of speech for instantaneous report production, with little
or no time lapse between the spoken and typed word. The Company is also a
remarketer of IBM hardware.
Sybase Corporation (Emeryville, CA) The Company is an Option Solutions(TM)
Partner with Sybase Corporation. This partnership enables Dynamic and Sybase
to deliver enterprise client/server solutions.
TriPath Imaging, Inc. (formerly AutoCyte, Inc.) (Burlington, NC) - The
Company has an Original Equipment Manufacturer (OEM) distribution agreement
with TriPath Imaging allowing the integration of the AutoCyte Image
Management System (AIMS) into DynamicVision for Pathology. Marketed under the
name PICSPlus, this solution combines sophisticated image management features
with telepathology capabilities. Through this agreement, the Company has the
exclusive rights to sell AIMS within the laboratory and anatomic pathology
information systems markets in the U.S. and Canada.
Sunquest Information Systems (Tucson, Arizona) The Company has a value-added
re-marketer agreement with Sunquest Information Systems (Sunquest). Under
the terms of the agreement, Sunquest exclusively markets and sub-licenses the
Company's CoPathPlus anatomic pathology solution to their existing base of
clients. Sunquest may also sell CoPathPlus, when bundled with their
laboratory information system, in the general U.S. healthcare market and on a
stand-alone product basis in the international market.
Keane Inc. (formerly First Coast Systems of Jacksonville, FL) Keane is an
authorized reseller of the Premier Series Laboratory Information System.
Through this agreement, Keane markets and sells the Premier Series as a
complement to their hospital information system solution.
MediHealth Outsourcing (King of Prussia, PA) Dynamic and MediHealth have an
agreement whereby Dynamic's document management and workflow solution,
DynamicVision for Information Management provides the cornerstone for
MediHealth to market health information management (medical records)
outsourcing services to Dynamic clients. These services include remote
coding, interim management, and complete department outsourcing.
Integrated Visions, Inc. (Sebastian, FL) Security in accessing the
DynamicVision for Information Management product line is enhanced through the
use of biometric authentication technology (finger image, voice and face
recognition) provided by Integrated Visions, Inc.
PenRad (Plymouth, MN) Through an OEM agreement, Dynamic markets the PenRad
mammography management application as an integrated component of the complete
radiology solution; DynamicVision for Radiology.
8
Talk Technology, Inc. (Brooklyn, NY) A strategic alliance with Talk
Technology, Inc., enables Dynamic to market and provide service and support
for an interfaced continuous speech recognition solution for the radiology
product line, DynamicVision for Radiology, and the pathology product line,
DynamicVision for Pathology.
FileLink Corporation (Bloomington MN) Dynamic is an authorized reseller of
FileLink Corporation's archive file management software which is used in
conjunction with Dynamic PACSPlus, a part of the radiology product line,
DynamicVision for Radiology.
Pegasus Imaging Corporation (Tampa, FL) The Company uses Pegasus Imaging
Corporation's wavelet compression technology in the web-based teleradiology
solution, WebSight, a component of Dynamic PACSPlus. PACSPlus is a part of
Dynamic's radiology product line, DynamicVision for Radiology.
Sales and Marketing
As of December 31, 1999, the Company had 25 full time employees in sales and
marketing related functions. The Company had 15 sales employees and 10
marketing employees. The compensation of the sales employees is
substantially dependent on the achievement of individual sales targets.
Marketing personnel perform telemarketing, proposal development,
demonstration coordination, develop business plans and product marketing
programs, competitive analyses, sales collateral, audio and video products,
coordinate trade shows, advertising, public relations, investor relations
activities, and administrative support.
The Company's sales cycle is typically six to eighteen months and includes
several steps: (i) initial contact and qualification; (ii) development of
proposal in response to request for a proposal or direct sales lead; (iii)
business problem requirements definition; (iv) product demonstrations; (v)
site visits; and (vi) contract preparation and negotiations. Members of the
Company's professional services, product management and sales support
departments, and members of executive management assist the sales force in
completing the proposal, conducting demonstrations and analyzing the
requirements. In support of the sales efforts, the Company advertises in
trade journals, participates in trade shows, publishes articles and provides
speakers for industry shows and conferences. In addition, the Company
receives qualified leads as well as support in proposal development,
demonstrations and site visits from its strategic business partners, which
include IBM, Sunquest Information Systems, TriPath Imaging, Keane, Inc
(formerly First Coast Systems) and others.
Customers
Dynamic currently serves more than 650 customers, most located in the United
States. Key customers include the Massachusetts General Hospital, Methodist
Hospital of Memphis, Orlando Regional Health System, University of North
Carolina Hospitals, University of Pittsburgh Medical Center Health System,
University of Illinois at Chicago Medical Center, Memorial Sloan-Kettering
Cancer Center, Advocate Health Care, Borgess Health Alliance, The Mayo Clinic
and Medical College of Virginia.
Competition
The market for information technology in the healthcare industry is intensely
competitive. Many of the Company's competitors have significantly greater
financial, research and development technical and marketing resources than
the Company. Competitors vary in size and in the scope and breadth of the
products and services they offer. The Company's systems compete both with
other technologies and with similar systems developed by other companies.
Other major information management companies, including the companies with
whom the Company has strategic relationships, may enter the markets in which
the Company competes. In addition, in the professional and technical
consulting segment, the Company competes with the consulting divisions of
national accounting firms as well as national and regional healthcare
specialty consulting firms.
Government Regulation
The United States Food and Drug Administration (the FDA) has issued a
guidance document addressing the regulation of certain computer products as
medical devices under the Federal Food, Drug and Cosmetic Act (the FFDCA).
To the extent that computer software is classified as a medical device under
applicable regulations, the manufacturers of such products are required,
depending upon the product, to: register and list their products with the FDA
(Class I), notify the FDA and demonstrate substantial equivalence to other
products on the market before marketing such products (Class II) or, obtain
FDA clearance by filing a Pre Market Application (PMA) that establishes the
safety and effectiveness of the product (Class III). As a result of the
characterization of certain of the Company's products as medical devices, the
Company's manufacturing facilities are registered with the FDA and its
manufacturing operations regarding devices are required to be in compliance
with the FDA's Quality System Regulations (QSR). The Company currently has
one product classified as a Class I Medical Device, Premier Laboratory
Information System, and two products currently classified as Class II Medical
9
Devices, PACSPlus and Transfusion Service Manager ("TSM"). On December 19,
1997, the FDA issued a letter of Substantial Equivalence to the Company for
the TSM product. This letter was the positive outcome of the 510(k)
submission process begun in March 1996. On December 8, 1998, the FDA issued
a letter of Substantial Equivalence for the Company's PACSPlus product. This
letter was the positive outcome of the Special 510(k) submission process
begun in June 1998. The most recent FDA on-site inspection of the Company's
Corporate Headquarters in Lake Mary, FL, occurred August 25-31, 1999, and
concluded without incident. As a part of the Development cycle, all
potential products, including the SurgiPlus InterOp data recording module,
undergo regulatory evaluation to determine their status as Medical Devices,
and when appropriate, are submitted to the FDA. There can be no assurance
that the Company ultimately will be able to obtain or maintain required FDA
approvals to market its products.
Intellectual Property
The Company relies upon trade secrets, copyright laws and confidentiality
agreements with employees and customers to protect its rights in its software
technology. The Company does not hold any patents nor has it filed
copyrights with respect to any of its software technology. Due to the rapid
pace of innovation within the software industry, the Company believes that
patent, trade secret and copyright protection are less significant than the
Company's ability to further develop, enhance and modify its current products
and other clinical information systems through the technology and creative
skills of its personnel. To minimize the possibility of third parties
imitating the Company's systems, the Company licenses object codes only and
does not license or otherwise distribute source codes.
The Company's employees are required to enter into confidentiality agreements
which prohibit the disclosure of confidential information and which require
employees to report and assign to the Company all concepts, developments,
discoveries and inventions conceived during their employment.
The Company has obtained federal trademark protection for DynamicVision(R),
CoPath(R), Maxifile(R), and Optima(R). There can be no assurance that the legal
protections and precautions taken by the Company will be adequate to prevent
misappropriation of the Company's technology. In addition, these protections
do not prevent independent third-party development of functionally equivalent
or superior technologies or services. The Company does not believe its
operations or products infringe on the intellectual property rights of
others. There can be no assurance that others will not assert infringement
or trade secret claims against the Company with respect to its current or
future products or that the Company will be successful in defending any such
claim.
Employees
As of February 15, 2000, the Company had 202 full time employees, of which 53
were employed in research and development, 102 in client services, 22 in
general and administrative and 25 in sales and marketing. None of the
Company's employees is represented by a labor union or subject to a
collective bargaining agreement. The Company has never experienced a work
stoppage and believes that its employee relations are good.
Factors Affecting Forward-Looking Statements
This report, and other reports, proxy statements and other communications to
stockholders, as well as oral statements made by representatives of the
Company, may contain forward-looking statements and other risks detailed from
time to time in the Company's filings with the Securities and Exchange
Commission, that are subject to risks and uncertainties, including, but not
limited to, the impact of competitive products and pricing, product demand
and market acceptance, new product development, reliance on key strategic
alliances, availability of products procured from third party vendors, the
healthcare regulatory environment, fluctuations in operating results and with
respect to, among other things, the Company's future revenues, operating
income and earnings per share, as well as plans and objectives of management.
Readers are cautioned not to place undue reliance on these forward-looking
statements, which reflect management's analysis only as of the date hereof.
The Company undertakes no obligation to publicly release the results of any
revisions to these forward-looking statements which may be made to reflect
events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events. The following are some, but not necessarily all, of
the factors that may cause the Company's actual results to vary materially
from those which are the subject of any such forward-looking statements.
An important element of the Company's business strategy has been and may
continue to be expansion through acquisitions, both to extend its customer
base and to acquire strategic technology. The Company's ability to expand
successfully through acquisitions depends on many factors including the
identification of appropriate acquisition opportunities, negotiation of
suitable terms and management's ability to effectively integrate and operate
the acquired businesses. The Company competes for acquisitions with other
companies, certain of which have significantly greater financial and
10
management resources. The Company's financial performance will be subject to
the risks of the performance of the acquired businesses as well as the
financial effects associated with integration of such businesses.
The healthcare industry is subject to changing political, economic and
regulatory influences, many of which relate to control of healthcare costs.
Such changes may affect operational aspects of the healthcare industry,
including procurement practices and the availability and/or allocation of
capital funds, which could result in greater selectivity, thus adversely
impacting the Company's ability to sell its products. The Company cannot
predict with any certainty what impact, if any, future regulation or
healthcare reform might have on its results of operations, financial
condition or business.
The Company's quarterly revenues and results of operations have varied
significantly as a result of a number of factors, including (i) the volume
and timing of systems sales and installations; (ii) the timing of client
acceptances; (iii) the length and complexity of the systems sales and
installation cycles; (iv) seasonal buying trends as a result of clients'
annual purchasing and budgeting practices. The Company expects that these
variations will continue for the foreseeable future. The Company recognizes
revenues from the services and custom software portion of system sales on a
percentage-of-completion method based upon completion of specified
milestones. As a result, the timing of revenue recognition varies
considerably and could be impeded by a number of factors, including
availability of Company personnel, the Company's need to allocate system
installation resources to other installations or to research and development
activities, availability of client personnel and other resources, and
complexity of the clients' needs and delays imposed by clients. Any trend of
delays in progress toward completing a material system installation or a
number of smaller installations could reduce the revenues recognized in any
given period and could have a material adverse effect on the Company's
business and results of operations. Because a significant percentage of the
Company's expenses, particularly employee compensation, is relatively fixed,
variations in the timing of systems sales and installations can cause
significant variations in operating results from quarter to quarter. If
total revenues are below expectations in any period, the Company's inability
to adjust spending to compensate fully for the lower revenues may magnify the
adverse effect of such a shortfall on the Company's results of operations.
Accordingly, the Company believes that period-to-period comparisons of
revenue and results of operations are not necessarily meaningful and should
not be relied upon as indicators of future performance.
The Company expects that the United States Food and Drug Administration
("FDA") is likely to become increasingly active in regulating computer
software that is intended for use in health care settings. In March 1994,
the FDA issued a letter advising that the FDA considers medical devices to
include software products intended for use in the manufacture of blood and
blood components or for the maintenance of data used to assist personnel in
making decisions concerning the suitability of blood donors and the release
of blood or blood components for transfusion or further manufacture. As
such, the FDA determined that manufactures and distributors of these
products, such as the Company, are subject to FDA regulation. The FDA can
impose extensive requirements governing pre- and post market conditions such
as device investigation, approval, labeling and manufacturing. Compliance
with these new requirements and any future requirements imposed by the FDA
could be costly and could delay or preclude the introduction of certain new
products. The Company is unable to determine at this time the effect, if
any, that these requirements may have on its business.
Competition in the Company's industry is subject to continual change in not
only the products and services offered but also in the manner in which
vendors are selected by customers. Accordingly, the Company's continued
success will be dependent on its ability to develop new products and services
on a timely basis and at competitive prices.
The Company's systems include applications that may relate to confidential
medical histories and treatment plans. Improper disclosure of this
information or any failure by the Company's systems to provide accurate and
timely information could result in claims against the Company by its clients
or their patients. A successful claim brought against the Company in excess
of its insurance coverage could have a material adverse effect on the
Company's business or results of operations, and even unsuccessful claims
could result in the expenditure of substantial funds in litigation and the
diversion of management time and resources. There can be no assurance that
the Company will not be subject to such claims in the future, that such
claims will not result in liability in excess of any insurance coverage
maintained by the Company with respect to such claims, that insurance will
cover such claims or that appropriate insurance will continue to be available
to the Company at commercially reasonable rates.
While the Company maintains insurance protecting against certain asserted
claims, there can be no assurance that its insurance coverage would
adequately cover any or all such claims asserted against the Company.
The Company must anticipate and adapt to evolving industry standards and new
technological developments. The market for the Company's products is
characterized by continued and rapid technological advances. The Company's
future success will depend in part on its ability to be responsive to these
technological developments and challenges, which could also lower the cost of
products and services or otherwise result in competitive pricing pressures.
11
The Company relies on a combination of trade secret, copyright and trademark
laws, together with nondisclosure, other contractual provisions and technical
measures to protect its proprietary rights in its products. There can be no
assurance that these protections will be adequate or that the Company
competitors will not independently develop technologies that are equivalent
or superior to the Company's technology. Although the Company believes that
its products and other proprietary rights do not infringe upon the
proprietary rights of third parties, there can be no assurance that third
parties will not assert infringement claims against the Company in the
future.
The stock market has, from time to time, experienced extreme price and volume
fluctuations, particularly in the high technology sector, which have often
been unrelated to the operating performance of particular companies. The
Company experiences fluctuations in its stock price related to these general
market swings as well as announcements of technological innovations, new
product introductions by the Company or its competitors, market conditions in
the computer software or hardware industries and healthcare reform measures.
These fluctuations may adversely effect the Company's ability to make
acquisitions utilizing its stock.
Item 2. Properties
The Company's corporate headquarters are located at 615 Crescent Executive
Court, Suite 600, Lake Mary, Florida 32746. The Lake Mary location consists
of approximately 53,800 square feet of office space under a lease that
expires March 1, 2005. In addition, the Company also maintains an office at
Two University Office Park, 51 Sawyer Road, Waltham, Massachusetts 02154 as
the Company's clinical solutions center. The Waltham location consists of
approximately 30,000 square feet under lease that expires November 30, 2004.
The Company believes that its current facilities are sufficient to meet its
near-term requirements.
Item 3. Legal Proceedings
In July 1997, the Company commenced a declaratory judgement action in Dakota
County, Minnesota District Court seeking a declaration that the Company had
properly terminated the services of an individual. The individual filed a
counterclaim and demanded $200,000 in settlement of a claim alleging breach
of contract, promissory estoppel and fraud. On October 20, 1999 judgement
was entered in favor of the Company.
As of the date hereof, there are no other material legal proceedings pending
against the Company. In the opinion of management, the legal proceedings in
which the Company is involved will not have a material effect on the
Company's consolidated financial statements.
Item 4. Submission of Matters to a Vote of Security Holders
No matter was submitted to a vote of the Company's security holders during
the fourth quarter of 1999.
12
FORM 10-K
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
PART II
Item 5. Market for Registrant's Common Stock and Related Stockholder Matter
(a) The information called for by this item is incorporated herein by
reference from page 52 of Exhibit 13 to this Form 10-K.
(b) As of March 2, 2000, there were approximately 3,700 shareholders of the
Company's Common Stock.
(c) The Company has declared no cash dividends on its common stock since its
inception and plans to continue to invest all earnings back into the Company
in the foreseeable future.
Item 6. Selected Financial Data
The information required by this item is incorporated herein by reference
from page 24 of Exhibit 13 to this Form 10-K.
Item 7. Management's Discussion and Analysis of Financial Condition and
Results of Operations
The information required by this item is incorporated herein by reference
from page 25 through page 32 of Exhibit 13 to this Form 10-K.
Item 7(A). Quantitative and Qualitative Disclosures About Market Risk
The information required by this item is incorporated herein by reference
from page 32 of Exhibit 13 to this Form 10-K.
Item 8. Financial Statements and Supplementary Data
The information required by this item is incorporated herein by reference
from page 33 through page 54 of Exhibit 13 to this Form 10-K.
Item 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure
There were no disagreements with accountants on accounting and/or financial
disclosures during 1998 or 1999.
On June 16, 1999 the Registrant's Audit Committee as authorized by the
Registrant's Board of Directors acting upon the recommendation of the
Registrant's current officers, approved a resolution to dismiss the
Registrant's Independent Accountant KPMG LLP.
One June 23, 1999 the Registrant engaged BDO Seidman, LLP as the principal
accountant to audit and report on the Registrant's consolidated financial
statements as of and for the year ended December 31, 1999.
KPMG LLP's reports on the Registrant's financial statements for the fiscal
years ended December 31, 1997 and 1998 were unqualified and there were no
disagreements with KPMG LLP on any matter of accounting principles or
practices, financial statement disclosure or auditing scope or procedure,
which, if not resolved to the satisfaction of the former accountant, would
have caused it to make reference to the subject matter of the disagreement in
connection with its report. The Registrant has authorized KPMG LLP to
respond fully to the inquiries of BDO Seidman, LLP with respect to their
engagement as the Registrant's Independent Accountant without limitation.
13
FORM 10-K
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
PART III
Item 10. Directors and Executive Officers of the Registrant
The information required by this item is incorporated herein by reference
from the Company's Proxy Statement for its 2000 Annual Meeting of
Shareholders.
Item 11. Executive Compensation
The information required by this item is incorporated herein by reference from
the Company's Proxy Statement for its 2000 Annual Meeting of Shareholders.
Item 12. Security Ownership of Certain Beneficial Owners and Management
The information required by this item is incorporated herein by reference from
the Company's Proxy Statement for its 2000 Annual Meeting of Shareholders.
Item 13. Certain Relationships and Related Transactions
The information required by this item is incorporated herein by reference from
the Company's Proxy Statement for its 2000 Annual Meeting of Shareholders.
14
FORM 10-K
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
PART IV
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K
The following documents are filed as a part of this report:
1. Financial Statements
-Independent Auditors' Reports on the financial statements.
-Balance Sheets as of December 31, 1998 and 1999.
-Statements of Operations for the years ended December 31, 1997, 1998
and 1999.
-Statements of Shareholders' Equity for the years ended December 31,
1997, 1998 and 1999.
-Statements of Cash Flows for the years ended December 31, 1997, 1998
and 1999.
-Notes to Financial Statements.
The Financial Statements listed above are all incorporated by reference to
pages 33 through 54 of Exhibit 3 to this Form 10-K.
2. Financial Statement Schedules
Index Schedule No. Page No.
Independent Auditors' Report on Financial -- 16
Statement Schedule as of and for the year
ended December 31, 1999
Independent Auditors Report on Financial -- 17
Statement Schedule as of and for the years
ended December 31, 1998 and 1997
Valuation and Qualifying Accounts II 18
All other schedules are omitted as the required information is inapplicable
or the information is presented in the financial statements or related notes
thereto.
3. Exhibits and Reports on Form 8-K
(a) Exhibits:
Exhibit 13: 1999 Annual Report to Security Holders.
(b) Reports on Form 8-K:
A Form 8-K, dated December 17, 1999, was filed by the
Registrant during the quarter ended December 31, 1999
reporting the resignation from the Company's Board of
Directors of Mr. David M. Pomerance for personal reasons.
15
INDEPENDENT AUDITORS' REPORT
Board of Directors
Dynamic Healthcare Technologies, Inc.:
The audit referred to in our report dated February 11, 2000 relating to the
financial statements of Dynamic Healthcare Technologies, Inc., which is
contained in Item 8 of this Form 10-K incorporated by reference the audit of the
financial statement schedule listed in the accompanying index. This financial
statement schedule is the responsibility of the Company's management. Our
responsibility is to express an opinion on this financial statement schedule
based upon our audit.
In our opinion such financial statement schedule presents fairly, in all
material respects, the information set forth therein.
/S/BDO SEIDMAN LLP
BDO SEIDMAN LLP
Orlando, Florida
February 11, 2000
16
INDEPENDENT AUDITORS' REPORT
Board of Directors
Dynamic Healthcare Technologies, Inc.:
Under date of February 19, 1999, we reported on the consolidated balance sheets
of Dynamic Healthcare Technologies, Inc. as of December 31, 1997 and 1998 and
the related statements of operations, shareholders' equity and cash flows for
the years then ended, as contained in the annual report on Form 10-K for the
year 1998. In connection with our audits of the aforementioned consolidated
financial statements, we have also audited the related 1997 and 1998 information
in the consolidated financial statement schedule as listed in the accompanying
index. This consolidated financial statement schedule is the responsibility of
the Company's management. Our responsibility is to express an opinion on the
1997 and 1998 information in this consolidated financial statement schedule
based on our audits.
In our opinion, such 1997 and 1998 information in the consolidated financial
statement schedule, when considered in relation to the basic 1997 and 1998
consolidated financial statements taken as a whole, presents fairly, in all
material respects, the information set forth therein.
/S/KPMG LLP
KPMG LLP
Orlando, Florida
February 19, 1999
18
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
VALUATION AND QUALIFYING ACCOUNTS
YEARS ENDED DECEMBER 31, 1997, 1998 AND 1999
Schedule II
<TABLE>
Balance At Charged to Write-Offs,
Beginning of Costs and Retirements & Balance At
Description Year Expenses Collections End of Year
Year Ended December 31, 1997:
Allowance for Doubtful
<S> <C> <C> <C> <C>
Accounts Receivable $ 326,102 $ -- $ 19,046 $ 307,056
Accumulated Amortization
of Capitalized Software
Development Costs $3,368,300 $1,484,276 $ 23,305 $4,829,271
Year Ended December 31, 1998:
Allowance for Doubtful
Accounts Receivable $ 307,056 $ 206,805 $ 153,861 $ 360,000
Accumulated Amortization
of Capitalized Software
Development Costs $4,829,271 $1,756,798 $ -- $6,586,069
Year Ended December 31, 1999:
Allowance for Doubtful
Accounts Receivable $ 360,000 $ 242,993 $ 143,232 $ 459,761
Accumulated Amortization
of Capitalized Software
Development Costs $6,586,069 $2,077,643 $ -- $8,663,712
</TABLE>
18
FORM 10-K
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
Commission File No. 0-12516
IRS E.I.N. 59-3389871
By: /S/PAUL S. GLOVER Date: March 9, 2000
Paul S. Glover
Vice President of Finance,
Chief Financial Officer and Secretary
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
Signature Title Date
/S/JERRY L. CARSON Chairman of the Board March 9, 2000
Jerry L. Carson
/S/MITCHEL J. LASKEY President, CEO, Treasurer & Director March 9, 2000
Mitchel J. Laskey
/S/PAUL S. GLOVER Vice President of Finance, CFO & Secretary March 9, 2000
Paul S. Glover
/S/THOMAS J. MARTINSON Director March 9, 2000
Thomas J. Martinson
/S/BRET R. MAXWELL Director March 9, 2000
Bret R. Maxwell
/S/DANIEL RAYNOR Director March 9, 2000
Daniel Raynor
19
FORM 10-K
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
INDEX TO EXHIBITS
Description of Exhibits Page Number
Exhibit 13 Annual Report to Shareholders of Dynamic Healthcare
Technologies, Inc. for the fiscal year ended
December 31, 1999. 22
20
FORM 10-K
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
EXHIBIT 13
Annual Report to Shareholders
of Dynamic Healthcare Technologies, Inc.
for the Fiscal Year Ended December 31, 1999
21
OUTSIDE FRONT COVER
Dynamic Healthcare Technologies, Inc.
1999 Annual Report
22
INSIDE FRONT COVER
Dynamic Healthcare Technologies, Inc. is a leader in providing advanced
information technologies for the healthcare industry. Dynamic's enterprise
information solutions enable healthcare providers to capture, manage and share
electronic health information across the continuum of care.
Contents
Company Profile.......................................................
Selected Financial Data...............................................
Fellow Shareholders...................................................
Focus & Execution Creating Value......................................
Management's Discussion and Analysis..................................
Financial Statements and Notes........................................
Independent Auditors' Report..........................................
Board of Directors and Officers.......................................
Shareholders Information..............................................
23
SELECTED FINANCIAL DATA
FIVE YEARS ENDED DECEMBER 31, 1999
(In thousands except per share data and current ratio)
The following selected financial data for the five years ended December 31,
1999, were derived from the financial statements of Dynamic Healthcare
Technologies, Inc. These data should be read in conjunction with Management's
Discussion and Analysis of Financial Condition and Results of Operations and the
financial statements, related notes and other financial information included
herein.
<TABLE>
1995 1996(1) 1997 1998 1999
<S> <C> <C> <C> <C> <C>
Operating Revenues $12,088 $19,826 $36,545 $25,829 $35,143
Net Earnings (Loss) from
Continuing Operations (590) (15,618) 1,043 (9,013) 854
Net Earnings (Loss) Per Common Share (0.09) (1.72) 0.06 (0.50) 0.04
Working Capital 2,274 9,191 6,534 (255) 2,078
Current Ratio 1.56 1.80 1.5 9.98 1.17
Total Assets 11,557 31,825 32,977 30,604 29,660
Long-Term Liabilities 2,786 591 454 1,871 1,545
Shareholders' Equity 4,703 19,771 21,423 14,626 15,921
</TABLE>
The Company has declared no cash dividends on common stock since its inception.
(1) Includes the operating results and related financial information since the
acquisitions of Dimensional Medicine, Inc. ("DMI"), on May 1, 1996 and
Collaborative Medical Systems, Inc. ("CoMed"), on December 17, 1996, including
the non-recurring write off of in-process research and development of 15,057,569
or $1.63 per common share, in connection with the CoMed acquisition. Both of
these acquisitions were accounted for as purchase business combinations.
24
Item 7.
MANAGEMENT'S DISCUSSION AND ANALYSIS FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
Overview
Dynamic Healthcare Technologies, Inc. ("Dynamic" or the "Company") is a
leading provider of Internet and image-, voice-, and web-enabled information
systems for clinical services departments and facilities. The Company's product
line is a suite of solutions for anatomic pathology, radiology, laboratory,
surgical services and health information management. In 1999, the Company
launched a strategic initiative to move into the e-Health arena by converging
its traditional clinical applications with emerging Internet technologies. The
resulting e-Health solutions enable physicians, clinicians, and departmental
staff both inside and outside the healthcare facility, to use Dynamic's systems
over the Internet, thereby extending their reach to remote hospitals, outreach
service locations, reference labs, physician offices and homes. An e-Health
solution set positions the Company to assume a leadership role in the multi-
billion dollar e-Health business to business (B2B) marketplace. The Company
is also moving forward with plans to package and deliver its software and
services on a "fee-per-use" basis through an Application Solution Provider
(ASP) model.
Dynamic's information systems contribute to higher quality and more cost-
effective delivery of care and make it possible to have access to information
"anytime/anywhere." Dynamic is headquartered in the greater Orlando area and
has a key operations and development center near Boston. The Company
provides support for all of its systems and also offers integration and other
consulting services.
Dynamic currently serves more than 650 customers, most located in the United
States. Key customers include Massachusetts General Hospital, Methodist
Hospital of Memphis, Orlando Regional Health System, University of North
Carolina Hospitals, University of Pittsburgh Medical Center Health System,
University of Illinois at Chicago Medical Center, Memorial Sloan-Kettering
Cancer Center, Advocate Health Care, Borgess Health Alliance, The Mayo Clinic
and Medical College of Virginia.
The Company was originally incorporated in California in 1977, reincorporated
in Nebraska in 1982 and subsequently reincorporated in Florida in 1996. The
Company's executive offices are located at 615 Crescent Executive Court,
Fifth Floor, Lake Mary, Florida 32746. Its telephone number is (407) 333-
5300 and its World Wide Web address is http://www.dht.com.
During 1997, the Company introduced new technology product releases in
virtually every market segment in which the Company competes. Well-
publicized healthcare information technology industry research indicates that
sales cycles for these products typically range from 6-18 months in duration.
The disruption of in-process sales cycles by the new products introduction in
1997 significantly impacted the Company's new system revenue for 1998.
During 1998, operations focused on perfecting the initial installations of
the products introduced in 1997, which further impacted revenue recognition
in 1998. However, during the fourth quarter of 1998, the Company realized
record new system sales bookings of $7.5 million and began 1999 with the
highest new systems backlog in the Company's history of more than $13.8
million. This together with more than $14.2 million in annualized customer
support revenue under contract positioned Dynamic to enter 1999 with a total
revenue backlog of $28 million, also the highest in the Company's history.
In addition, during 1998 the Company reengineered its internal process of
development, customer support and product installations. This reengineering
resulted in the consolidation of three facilities into the Lake Mary
headquarters, a common structure to the Company's product line which
permitted a higher level of cross utilization of technical professionals for
development, support and installation services, and was expected to provide
significant anticipated future cost efficiencies. Base quarterly operating
expenses, defined as total operating expenses less the cost of products sold,
sales commissions and customer billable expenses, was reduced to a budgeted
amount of approximately $6.4 million for the first quarter of 1999 compared
to $8.1 million in the first quarter of 1998.
25
During the third quarter of 1999 the Company announced a realignment plan.
This realignment was designed to provide a single focus to the development,
marketing, sales and support of the Company's information systems. It also
established specific cost reductions, revenue improvement and customer
satisfaction objectives and anticipated future cost efficiencies. In
connection with the plan, a total of seventeen employees were terminated and
the Company incurred $524,000 of one time termination benefits.
The Company's revenues are derived from (i) computer equipment sales and
support, (ii) application software licenses, (iii) software support and (iv)
services and other revenues. The Company generally recognizes revenues from
computer equipment sales at the time the products are shipped. Computer
system equipment sales and support revenues include hardware support
contracts for a specific period from which revenue is recognized ratably over
the corresponding contract period. Application software license revenues are
recognized when application software is delivered to the customer.
Installation and training service revenues, included with application
software licenses, are recognized as the services are performed. Software
support revenues principally include contracts for remote dial-up problem
diagnosis and maintenance and corrective support services, each of which
covers a specified period for which revenue is recognized ratably over the
corresponding contract period. Services and other revenues include project
management, training, consulting, custom programming services, post-contract
support obligations and others services, which are provided under separate
contract and are recognized as services are performed. Revenue from
professional services and maintenance and support services typically increase
as the number of installed systems increases.
Cost of products sold includes the cost of hardware sold, costs of third
party software licenses and hardware support subcontracts. Client service
expense includes the direct and indirect costs associated with implementation
and support personnel. Software development costs include the direct and
indirect salaries and wages of software research and development personnel,
direct research and development expenses, reduced by capitalized software
development costs. Software development costs are expensed until such time
as technological feasibility is established and then are capitalized in
compliance with Statement of Financial Accounting Standards No. 86
"Accounting for Costs of Computer Software to be Sold, Leased or Otherwise
Marketed." Software amortization is separately stated. Sales and marketing
costs include direct and indirect salaries, commissions, joint marketing
costs, advertising, trade show costs, user group cost and travel and
entertainment expenses related to the sale and marketing of the Company's
products and services. General and administrative expenses include salaries
and expenses for corporate administration, financial, legal and human
resources.
The sales cycle for the Company's systems is typically six to eighteen months
from initial contact to contract signing. The product delivery cycle is
variable. Based on the customer's implementation plan, product delivery may
take two or more years, particularly with enterprise-wide electronic
healthcare record solutions involving significant and continuing customer
service requirements. Accordingly, the product delivery cycle depends upon
the combination of products purchased and the implementation plan defined by
the customer in the master sales agreement. Each customer contract is
separately negotiated. The installation schedules for clinical information
systems, or departmental electronic healthcare record implementations,
typically require six to twelve months. Under its standard master sales
agreement, the Company generally receives a partial payment upon execution of
the agreement, a hardware installment payment upon delivery of hardware,
installation progress payments upon the completion of defined milestones and
final payment, which may vary with each contract.
26
Results of Operations
The following table sets forth, for each of the periods indicated, certain
selected statement of operations data expressed as a percentage of total
operating revenues:
<TABLE>
1997 1998 1999
Operating revenues:
<S> <C> <C> <C>
Computer system equipment sales and support 14.1 % 10.2 % 12.3 %
Application software licenses 35.4 20.9 27.7
Software support 30.0 45.4 33.3
Service and other 20.5 23.5 26.7
Total operating revenues 100.0 100.0 100.0
Costs and expenses:
Cost of products sold 14.5 12.6 17.8
Software amortization 4.1 6.8 5.9
Client services expenses 31.0 42.4 28.1
Software development costs 12.1 18.9 13.4
Sales and marketing 24.9 36.5 18.7
General and administrative 12.5 17.8 11.6
Realignment costs -- -- 1.5
Total costs and expenses 99.1 135.0 97.0
Operating income (loss) 0.9 (35.0) 3.0
Other income (expense) 2.0 0.1 (0.5)
Income taxes -- -- --
Net earnings (loss) 2.9 % (34.9) % 2.5 %
</TABLE>
27
Year ended December 31, 1999 compared to the Year Ended December 31, 1998
Revenues. During the year ended December 31, 1999 the Company reported
revenues of $35,143,000, an increase of $9,314,000 or 36% from revenues of
$25,829,000 for 1998. The Company's radiology system revenues increased by
$4,416,000, from $5,063,000 recognized during the 1998 to $9,479,000
recognized during 1999. Pathology revenue for 1999 increased by $3,909,000
to $14,735,000 from $10,826,000 during 1998. Similarly, laboratory
information system revenues for 1999 also increased by $643,000 to $8,245,000
from $7,603,000 during 1998. Revenues from the Records Plus product line
increased by $592,000 from $1,934,000 to $2,526,000 comparing 1998 to 1999,
respectively. As previously mentioned, during 1997 the Company introduced
new technology product releases in virtually every market segment in which
the Company competes. Lengthy initial sales cycles significantly impacted
1998 performance, while record fourth quarter 1998 sales bookings, and the
resulting record high new systems backlog as of December 31, 1998, resulted
in increased system implementations during 1999.
Computer system equipment sales and support revenues increased by $1,659,000
to 12.3% of total revenues for 1999 compared to 10.2% for 1998. Management
attributes the increase to the increased implementation of new system sales
and does expect a higher involvement in the delivery of computer hardware to
customers in connection with the Company's increasing emphasis of offering a
sole source solution to customers.
Application software license revenue during 1999, increased by $4,349,000
over 1998, from $5,396,000 to $9,745,000, and similarly service and other
revenue increased by $3,313,000 to $9,386,000 from $6,073,000. These
increases principally result from the increased implementation of new system
sales.
Software support revenues modestly decreased by $7,000 to $11,716,000 for
1999, compared to $11,723,000 for 1998. During 1998 the Company announced
the discontinuance of support for a limited offering of legacy laboratory and
financial products in connection with Year 2000 remediation efforts.
Management expects support revenues to grow with the implementation of new
system sales. As of December 31, 1999, the recurring annualized billable
support base was $12.3 million, and an additional $2.3 million of annualized
software support revenue is anticipated to be generated from delivery of the
Company's existing new systems backlog.
Cost of Products Sold. Cost of products sold as a percent of total revenues
for 1999 increased to 17.8% from 12.6% for 1998. Hardware and application
software license revenues during 1999 similarly increased to 40.0% from 31.1%
of total revenues for 1998, due to the significant increase in new system
implementations.
Client Services Expense. Client services expense for 1999 decreased
$1,078,000 to $9,880,000 from $10,958,000 for 1998, decreasing as a
percentage of sales from 42.4% to 28.1%. The Company previously reported
decreased staffing in connection with the re-engineering and cost reduction
plan completed in 1998. Product installation, delivery and support services
were standardized along all product lines as the Company centralized these
functions.
Software Development Costs. Software development costs for 1999 decreased to
13.4% of total operating revenues from 18.9% incurred during 1998. This
$180,000 net decrease in software development expense resulted despite a
$1,078,000 reduction in capitalized software development costs from
$3,174,000 capitalized during 1998 to $2,096,000 capitalized during 1999,
which increased the expense. In effect, a real reduction in total software
development departmental costs of $1,258,000 occurred in 1999, as compared to
1998. Although development efforts continue as part of the Company's overall
growth strategy, including enhancements to existing product lines and toward
completion of the Company's SurgiPlus product, this reduction in the level of
investment in new product development reflects the relatively recent
wholesale product line introductions made by the Company.
Sales and Marketing. Sales and marketing costs for 1999 as a percentage of
total revenues, decreased to 18.7% from 36.5% for the same period of 1998.
This decrease of $2,840,000 from $9,430,000 to $6,590,000 in sales and
marketing expenses is despite an increase in sales commissions incurred for
1999 of $462,000 from $1,063,000 incurred during 1998 to $1,525,000 incurred
during 1999, resulting from increased sales closings. This translates to a
base sales and marketing cost reduction of approximately $3,302,000
attributed to the sales realignment program undertaken in 1998, in connection
with the Company's cost reduction plan.
28
General and Administrative Expenses. General and administrative expenses for
1999 decreased by $536,000 and decreased to 11.6% of total revenues from
17.8% incurred during 1998. This decrease was despite an increase of
$382,000 in amounts accrued under the Company's Management Incentive
Compensation Plan ("MIC Plan"). The Company did not pay any MIC Plan
compensation for 1998. General and administrative costs for 1999 compared to
the same period in 1998, include reductions in salaries and professional
services of $544,000, office rent expense of $164,000 telephone expenses of
$269,000, supplies of $72,000 and mail delivery costs of $49,000, principally
attributed to the office consolidation and realignment efforts.
Realignment Costs. During the third quarter of 1999 the Company announced a
realignment plan. This realignment was designed to provide a single focus to
the development, marketing, sales and support of the Company's information
systems. It also established specific cost reductions, revenue improvement
and customer satisfaction objectives and anticipated future cost
efficiencies. In connection with the plan, a total of seventeen employees
were terminated and the Company incurred $524,000 of one time termination
benefits.
Other Income (Expense). The Company incurred $202,000 of net other expense
for 1999 compared to $41,000 of net other income reported for 1998. Net
interest income was $180,000 during 1998 as compared to net interest expense
during 1999 of $176,000 due to the cash used by operating and investing
activities during 1998, and increased borrowings on the line of credit during
1999. In addition, the Company incurred approximately $139,000 in losses on
sale of fixed assets in connection with the office consolidation in 1998 and
$26,000 in 1999.
Year Ended December 31, 1998 Compared to the Year Ended December 31, 1997
Revenues. During the year ended December 31, 1998 the Company reported
revenues of $25,829,000 a decrease of $10,716,000 from revenues for the year
ended December 31, 1997. During 1997, the Company recognized initial
pathology application software license revenue of $2,777,000 under the value
added re-marketing agreement with Sunquest Information Systems, Inc. (the
"Sunquest Agreement"), and approximately $3,925,000 of revenue from pathology
deliveries to the United States Department of Defense ("DOD"), hospitals
under a sub-contract to the United States Defense Supply Service. During
1998, only $202,000 of revenue was recognized under the Sunquest Agreement.
This represents $100,000 of revenue from licenses sold by Sunquest and
$102,000 from software support to Sunquest. In addition, government revenue
of only $1,299,000 was recognized during 1998.
Computer system equipment sales and support revenues decreased to 10.2% of
total revenues for 1998, compared to 14.1% for 1997, a decline of $2,517,000.
Neither the Sunquest Agreement nor deliveries to the Department of Defense
hospitals had any associated hardware revenue. The disruption of in-process
sales cycles by the new product introductions in 1997 significantly impacted
the Company's new system revenue for 1998, and new system sales have
historically been more hardware intensive than upgrades and add-on sales.
Application software license revenue during 1998, decreased by $7,521,000
from $12,917,000 in 1997 to $5,396,000. The Company recognized initial
pathology application software license revenue of $2,777,000 under the
Sunquest Agreement and $100,000 of additional licenses thereunder during
1997. Only $100,000 of application software license revenue was recognized
under the Sunquest Agreement during 1998. Also, during 1998, the Company
recognized only $27,000 of pathology application software license revenue
from government customers. This represents a $1,902,000 decrease from the
$1,929,000 of application software license revenue recognized during 1997
through deliveries under a completed U.S. Government sub-contract agreement.
In addition, other pathology application software license revenue decreased
by $750,000 principally due to the timing of sales cycles following the
introduction of the CoPath Client Server product in March 1997. As a result,
pathology application software license revenue decreased by $5,429,000.
Laboratory software application license revenue for 1998 increased by
$15,000. The Premier Series laboratory information system was acquired in
May 1997 with the acquisition of Dynacor, Inc. accounted for as a pooling of
interests. Initial new laboratory sales cycles were disrupted by the
consolidation process and integration with the Company's LabPro 2000
laboratory information system. The increase in laboratory system application
revenues during 1998 has principally resulted from successful customer
migrations. Radiology software application license revenues for 1998
declined by $1,344,000 compared to 1997. This primarily resulted from the
introduction of the new RadPlus client server version released for general
availability in December 1997 disrupting sales cycle for the older
technology. In addition, a multi-site radiology information system sale
resulted in $1,488,000 of application software license revenue during 1997.
29
There was no multi-site radiology revenue during 1998. Electronic health
record application software license revenues declined by $717,000 due to
lengthening sales cycles caused by market impacts related to year 2000
concerns, the growing influence of managed care, and new product releases.
Software support revenues increased $745,000 to $11,723,000 for 1998,
compared to $10,978,000 for 1997. This increase is principally attributable
to successful implementations of new systems. As of December 31, 1998, the
recurring annualized billable support base was $12.1 million, with an
additional $2.1 million of annualized software support revenue anticipated to
be generated from delivery of the Company's existing new systems backlog.
Service and other revenues decreased by $1,423,000 to $6,073,000 from
$7,496,000. This decrease principally results from the training and
implementation services in connection with system installations to the DOD
hospitals completed in 1997. There was no such corresponding revenue during
1998.
Cost of Products Sold. Cost of products sold as a percent of total revenues
for 1998 decreased to 12.6% from 14.5% for the same period 1997. Hardware
revenues during 1998 similarly decreased to 10.2% from 14.1% of total
revenues for 1997, due to the decline in new system revenues as previously
discussed. Third party product costs also expanded during 1998 as the
Company completed a variety of interfaces to strategic software technology
partners.
Client Services Expense. Client services expense for 1998 decreased
$363,000 to $10,958,000 from $11,321,000 for 1997, increasing as a percentage
of sales from 31.0% to 42.4%. The Company previously reported increased
staffing in connection with the 1996 acquisition of DMI and CoMed, the
introduction of the DynamicVision product line in November 1996, and new
product releases in 1997. During 1997, the Company released for general
availability client server versions of CoPath (March 1997), and RadPlus
(December 1997), and new releases of PACSPlus (October 1997), and Dynamic
RecordPlus (October 1997). The unanticipated elongation of initial product
sales cycles for these new products resulted in a significant decline in
quarterly revenues and a disproportionate burden in client services expense.
However, the Company decreased client services expenses while introducing
these new products.
Software Development Costs. Software development costs for 1998 increased to
18.9% of total operating revenues from 12.1% incurred during 1997.
Development efforts continued as part of the Company's overall growth
strategy. As such, the Company capitalized $3,174,000 or 39.4% of total
software development costs during 1998 compared to $3,906,000 or 46.9% of
total software development costs for 1997. The development effort during
1998 resulted in new releases and enhancements to the Company's client server
products.
Sales and Marketing. Sales and marketing costs for 1998 as a percentage of
total revenues, increased to 36.5% from 24.9% for 1997. During 1997, the
Company expanded and trained a national sales and marketing force in
connection with the Company's external growth plans, in preparation for the
launch of the Company's latest product releases. This resulted in an
increase in sales and marketing costs incurred during 1998 of $307,000 as
compared to similar costs for 1997.
General and Administrative Expenses. General and administrative expenses for
1998 increased by $51,000 to 17.8% of total revenues from 12.5% incurred
during 1997. During 1998 the Company completed a functional reorganization
and streamlining plan. The Company re-engineered its internal development,
customer support and product installation processes, resulting in
consolidation of three facilities into the Lake Mary headquarters. The re-
engineering accompanied the progression to a common structure to Dynamic's
product line, a move which permits more cross utilization of technical
professionals for development, support and installation services, and is
expected to provide significant future cost efficiencies. Base quarterly
operating expenses - defined as total operating expenses less the cost of
products sold, sales commissions and customer billable expenses - were
reduced to approximately $6.4 million for the first quarter of 1999 compared
to $8.1 million during the first quarter of 1998. The cost savings from
completion of the plan, together with a $279,000 reduction in expenses
accrued under the Company's management incentive compensation plan for 1998,
were more than offset by increases in bad debt charges of $207,000,
teambuilding expenses of $112,000, $125,000 in litigation settlement costs
with the Company's former President and CEO, and $319,000 in non-recurring
severance and termination benefits incurred in connection with the plan.
30
Other Income (Expense). Net other income for 1998 decreased by $690,000 to
$41,000, as compared to $731,000 for 1997. The Company incurred
approximately $139,000 in aggregate losses on sale and abandonment of fixed
assets in connection with the office consolidation activities completed
substantially during the third quarter of 1998. Net interest income
decreased by $509,000 during 1998 principally due to the cash used by
operating and investing activities. In addition, net interest expense and
financing costs increased by $42,000 principally due to amortization of
deferred financing costs and interest charges associated with the line of
credit established in July 1998.
Liquidity and Capital Resources
As of December 31, 1999 the Company had cash equivalents of $1,818,209 and
working capital of $2,077,628, and a working capital ratio of 1.17 to 1.
Accounts receivable and unbilled receivables as of December 31, 1999
increased from similar balances on December 31, 1998 by $2,154,000, or an
increase of 22.9%. These balances, however, as a percentage of the Company's
total annualized revenues decreased to 33.0% as of December 31, 1999 compared
to 36.5% one year prior. As a result, days sales outstanding in accounts
receivable and unbilled receivables decreased to120.3 days as of December 31,
1999, compared to 133.2 days as of December 31, 1998. Customer Year 2000
remediation efforts resulted in a significant fourth quarter 1999
concentration of billing milestones associated with completion of live
installations prior to year end.
Contracts receivable as of December 31, 1999 decreased $869,000 to $897,000
as compared to the balance of $1,766,000 on December 31, 1998. The Company
entered into a licensing agreement with Sunquest Information Systems, Inc.
resulting in initial licensing fees receivable in three installments of
$1,000,000 each. The first installment was collected upon signing on
February 7, 1997, the second installment was collected in 1998, and the final
installment was collected in the first quarter of 1999. The remaining change
in contracts receivable is attributable to scheduled collections on monthly
installment receivables from customers.
Other current assets as of December 31, 1999 decreased $596,000 to $717,000
from the 1998 year end balance of $1,313,000. Deferred sales commissions
declined by $375,000 and resale inventory declined by $226,000. These
decreases occurred principally as a result of the decrease in fourth quarter
new systems sales bookings made during 1998 of $7.5 million compared to the
$3.4 million in such bookings made during the fourth quarter of 1999.
Customer focus on Year 2000 remediation efforts contributed to this decrease
in new system sales bookings.
During 1999 the Company capitalized $2,096,000 of software development costs
and purchased $281,000 of additional property and equipment. Significant
development efforts resulted in new releases and significant enhancements in
both the RadPlus and CoPathPlus products. In addition, enhancements
continued on PacsPlus, WebSight, Premier Series, RecordPlus and AccessPlus
(formerly DynamicVision Desktop). The Company plans to significantly advance
development of the perioperative information management system SurgiPlus and
continues to enhance RadPlus, CoPathPlus, PACSPlus, WebSight and RecordPlus
in 2000. No significant property purchases are currently planned.
Accounts payable and accrued expenses decreased $1,190,000 to $3,042,000 as
of December 31, 1999 from $4,232,000 as of December 31, 1998. In connection
with the consolidation of Maitland, Apple Valley and Minnetonka offices to
Lake Mary, Florida, as of December 31, 1998 the Company accrued $185,000 of
lease termination costs and $175,000 of build-out costs, which were paid in
1999. Also included in accrued expenses as of December 31, 1998, was
approximately $213,000 of severance and termination benefits associated with
the Company's process re-engineering and cost reduction plan, also paid in
1999. In addition, commissions payable as of December 31, 1999 decreased by
$375,000 compared to the balance one year prior, principally as a result of
record new system sales bookings of $7.5 million made during the fourth
quarter of 1998. New system sales bookings during the fourth quarter of 1999
were $3.4 million.
Advanced billings as of December 31, 1999 decreased by $441,000 to $1,387,000
from the 1998 year end balance of $1,828,000. This resulted principally from
the decline in customer deposits on hand at December 31, 1999 compared to
those resulting from the record fourth quarter sales bookings in 1998.
31
As of December 31, 1999 the Company reported $983,000 of total current and
non-current deferred lease incentives, and $1,173,000 on December 31, 1998.
The lessor, in connection with the new Lake Mary office, provided
approximately $1,237,000 of lease incentives which are being amortized evenly
over the 78 month lease life, which began on September 1, 1998, as a
reduction in office rent expense.
During 1999, the Company received $297,000 in proceeds from the exercise of
Director and employee options and warrants and paid $160,000 in preferred
stock dividends.
During 1999 the employer match contribution of $304,998 to the Company's
401(k) defined contribution savings plan was made through the issuance of
194,713 shares of the Company's common stock at an average price of $1.57 per
share.
As of December 31, 1999 the Company had net operating loss carryforwards for
federal income tax purpose of approximately $19.6 million, which can be used
to offset Federal taxable income in future years. Future equity offerings
combined with sales of the Company's equity during the preceding years may
cause changes in ownership under Section 382 of the Internal Revenue Code of
1986, as amended, which will limit the use of the Company's net operating
loss carryforward existing as of the date of the ownership change. In the
event the Company has taxable income in the future, a change of ownership
under Section 382 may result in the application of such limitations and could
have a material adverse effect on the Company.
Management believes that existing cash, and funds available from alternative
financing options, together with funds expected to be generated by operations
will be sufficient to meet operating requirements for at least the next
twelve months.
Inflation and Changing Prices
The Company believes that the general state of the economy and inflationary
trends have only a limited effect on its business. Historically, inflation
has not had a material effect on the Company. Changing prices of computer
hardware could have a material effect on the cost of materials sold and the
related selling price of software and hardware sales.
Year 2000
The Company did not experience nor does it currently anticipate any material
adverse effects on the Company's business, results of operations, or
financial condition as a result of Year 2000 issues involving its internal
use systems, third party products nor any of its software products. Costs
incurred in readying for Year 2000 uncertainties, including contingency
planning and remediation efforts were expensed as incurred. The Company does
not anticipate any material costs remaining in connection with Year 2000
uncertainties.
Market Risk
The Company is exposed to interest rate changes primarily as a result of its
variable rate line of credit used to finance the Company's short-term working
capital needs and general corporate purposes. The Company's interest rate
risk management objectives is to limit the impact of interest rate changes on
earning and cash flows and to lower its overall borrowing costs.
The Company's market risks associated with its line of credit borrowings
outstanding is that the interest rate under the line of credit agreement is
based on the prime rate (8.5% as of December 31, 1999). The line of credit
agreement expires on April 23, 2000. Fair value of the line of credit as of
December 31, 1999 was equal to its carrying value of $700,000.
32
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
BALANCE SHEETS
DECEMBER 31, 1998 AND 1999
<TABLE>
1998 1999
ASSETS
Current assets:
<S> <C> <C>
Cash and cash equivalents $ 1,962,426 $ 1,818,209
Accounts receivable, net 6,847,498 8,590,441
Unbilled receivables 2,578,078 2,989,547
Contracts receivable - current 1,150,754 155,344
Other current assets 1,313,364 717,578
Total current assets 13,852,120 14,271,119
Property and equipment, net 5,167,436 4,107,481
Capitalized software development costs, net 9,247,578 9,266,284
Goodwill, net 1,663,032 1,255,483
Contracts receivable - non-current 615,645 741,444
Other assets 58,469 18,114
$ 30,604,280 $29,659,925
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued expenses $ 4,231,540 $ 3,041,799
Deferred revenue 6,729,436 6,577,199
Advance billings 1,828,351 1,387,119
Line of credit 856,000 700,000
Deferred lease incentives - current 190,231 190,231
Other 271,735 297,143
Total current liabilities 14,107,293 12,193,491
Deferred lease incentives - non-current 982,862 792,632
Other 888,358 752,538
Total liabilities 15,978,513 13,738,661
Shareholders' equity:
Series C redeemable convertible preferred
stock ($.01 par value; issued and
outstanding 1,000,000 shares with an
aggregate liquidation preference of
$2,000,000, as of December 31, 1999
and a $.16 per share annual dividend). 1,811,327 1,811,327
Common stock ($.01 par value; authorized
40,000,000 shares; issued and outstanding
18,271,251 and 18,814,887 shares in 1998
and 1999, respectively). 182,713 188,149
Warrants 3,000 3,000
Additional paid-in capital 44,699,416 45,135,109
Deficit (32,070,689) (31,216,321)
Total shareholders' equity 14,625,767 15,921,264
$ 30,604,280 $29,659,925
</TABLE>
See notes to financial statements.
33
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 1997, 1998 AND 1999
<TABLE>
1997 1998 1999
Operating revenues:
Computer system equipment
<S> <C> <C> <C>
sales and support $ 5,154,256 $ 2,637,601 $ 4,296,500
Application software licenses 12,917,390 5,396,122 9,745,107
Software support 10,977,540 11,722,897 11,715,631
Services and other 7,495,923 6,072,679 9,386,162
Total operating revenues 36,545,109 25,829,299 35,143,400
Costs and expenses:
Cost of products sold 5,321,053 3,242,556 6,237,188
Software amortization 1,484,276 1,756,798 2,077,643
Client services expense 11,321,158 10,958,132 9,880,115
Software development costs 4,429,274 4,889,673 4,709,784
Sales and marketing 9,123,366 9,430,307 6,589,688
General and administrative 4,554,028 4,605,237 4,068,990
Realignment costs -- -- 523,569
Total costs and expenses 36,233,155 34,882,703 34,086,977
Operating income (loss) 311,954 (9,053,404) 1,056,423
Other income (expense):
Interest expense and financing costs (51,661) (94,049) (277,075)
Gain (loss) on disposal of property 28,100 (139,063) (25,940)
Interest income 754,565 273,826 100,960
Total other income (expense) 731,004 40,714 (202,055)
Earnings (loss) before income taxes 1,042,958 (9,012,690) 854,368
Income taxes -- -- --
Net earnings (loss) $ 1,042,958 $ (9,012,690) $ 854,368
Net earnings (loss) available for
common shareholders $ 1,042,958 $ (9,080,245) $ 694,368
Earnings (loss) per common share
Basic and diluted $ 0.06 $ (0.50) $ .04
Weighted average number of common
shares outstanding 17,905,214 18,127,641 18,578,573
</TABLE>
See notes to financial statements
34
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
STATEMENTS OF SHAREHOLDERS' EQUITY
YEARS ENDED DECEMBER 31, 1997, 1998 AND 1999
<TABLE>
Additional
Series CM Series C Common Paid-In
Preferred Preferred Warrants Stock Capital Deficit
Balance,
<S> <C> <C> <C> <C> <C> <C>
December 31, 1996 $ 60 $ - $ - $170,072 $43,701,731 $24,100,957
Conversion of Series
CM Preferred Stock (60) - - 5,650 (5,590) -
Exercise of Stock
Options & Warrants - - - 3,721 384,387 -
Employee Stock
Purchase Plan - - - 639 220,179 -
Net income - - - - - 1,042,958
Balance,
December 31, - - - 180,082 44,300,707(23,057,999)
Issuance of Series C
Preferred Stock and
Warrants in Private
Placement Transaction - 1,811,327 3,000 - - -
Exercise of Stock
Options - - - 271 54,167 -
Employee Stock
Purchase Plan - - - 510 80,523 -
Employee 401(k)
Plan Match - - - 1,850 331,574 -
Preferred Stock
Dividends - - - - (67,555) -
Net loss - - - - - (9,012,690)
Balance,
December 31, 1998 - 1,811,327 3,000 182,713 44,699,416(32,070,689)
Exercise of
Stock Options - - - 2,077 211,298 -
Employee Stock
Purchase Plan - - - 1,280 82,251 -
Employee 401(k)
Plan Match - - - 2,079 302,144 -
Preferred Stock
Dividends - - - - (160,000) -
Net income - - - - - 854,368
Balance,
December 31, 1999 $ -$1,811,327$ 3,000 $188,149 $45,135,109$(31,216,321)
</TABLE>
See notes to consolidated financial statements.
35
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 1997, 1998 AND 1999
<TABLE>
1997 1998 1999
CASH FLOWS FROM OPERATING ACTIVITIES:
<S> <C> <C> <C>
Net earnings (loss) $ 1,042,958 $ (9,012,690) $ 854,368
Adjustments to reconcile net earnings
(loss) to net cash Provided (used)
by operating activities:
Depreciation and amortization 3,016,713 3,323,374 3,571,501
Book value of disposed property 20,074 181,828 66,249
Employer 401(k) contributions not
requiring cash -- 333,424 304,224
Provision for doubtful accounts
receivable -- 206,805 242,993
Changes in assets and liabilities:
Accounts receivable (440,096) (987,998) (1,985,936)
Unbilled receivables (788,889) 322,624 (411,469)
Contracts receivable (2,399,515) 1,325,952 869,611
Other 73,144 (194,955) 805,018
Accounts payable and accrued expenses 193,219 1,208,181 (1,189,741)
Deferred revenue 1,302,856 273,316 (152,237)
Advance billings (1,718,541) 568,475 (441,232)
Net cash provided (used) by
operating activities 301,923 (2,451,664) 2,533,349
CASH FLOWS FROM INVESTING ACTIVITIES:
Capitalized software development costs(3,906,254) (3,174,028) (2,096,349)
Purchases of property and equipment (1,841,306) (1,142,941) (280,828)
Restricted cash released/(deposited) 60,000 -- --
Net cash used by investing
activities (5,687,560) (4,316,969) (2,377,177)
CASH FLOWS FROM FINANCING ACTIVITIES:
Borrowings (repayments) under line of
credit, net -- 856,000 (156,000)
Proceeds from issuance of common stock 608,926 135,471 296,905
Proceeds from issuance of Series C
Preferred Stock and Warrants -- 1,814,327 --
Payment of preferred stock dividends -- (67,555) (160,000)
Borrowings (repayments) capital lease
obligations and other debt (208,040) (472,869) (281,294)
Net cash provided (used) by
financing activities 400,886 2,265,374 (300,389)
Net increase (decrease) in cash and
cash equivalents (4,984,751) (4,503,259) (144,217)
Cash and cash equivalents,
beginning of year 11,450,436 6,465,685 1,962,426
Cash and cash equivalents, end of year $ 6,465,685 $ 1,962,426 $ 1,818,209
SUPPLEMENTAL DISCLOSURES OF
CASH FLOW INFORMATION:
Interest paid $ 51,661 $ 94,049 $ 271,951
NON-CASH TRANSACTIONS:
Furniture and fixtures under
capital lease $ -- $ 492,495 $ --
Leasehold incentives received $ -- $ 1,236,503 $ --
</TABLE>
See notes to financial statements.
36
DYNAMIC HEALTHCARE TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS
YEARS ENDED DECEMBER 31, 1997, 1998, AND 1999
A. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business - Dynamic Healthcare Technologies, Inc. ("Dynamic" or the "Company")
is a leading provider of mission-critical healthcare information systems for
clinical services departments and facilities. The Company's product line,
DynamicVision(R), is a suite of image-, voice-, and web-enabled systems for
anatomic pathology, radiology, laboratory, surgical services and health
information management. Dynamic is headquartered in the greater Orlando area
and has a key operations and development center near Boston. The Company
provides support for all of its systems and offers integration and other
consulting services.
The Company - On May 1, 1996, Dimensional Medicine, Inc. ("DMI") was
purchased by and merged into DMI Acquisition Corporation ("DMIAC"), a newly
formed wholly owned subsidiary of the Registrant. The transaction was
consummated by purchasing all of the outstanding common stock and retiring
and assuming certain debt obligations of DMI. The acquisition has been
accounted for using the purchase method. On September 2, 1996, DMIAC was
merged with and into the Company.
On December 17, 1996, Collaborative Medical Systems, Inc. ("CoMed") was
purchased by and merged into Collaborative Medical Systems Corp. ("CMSI"), a
newly formed wholly owned subsidiary of the Registrant. The transaction was
consummated by purchasing all of the outstanding stock of CoMed using both
available cash, and common and preferred stock of the Company. The
acquisition was accounted for using the purchase method. On September 25,
1999 CMSI was merged with and into the Company
Accounts Receivable - Accounts receivable is stated at net book value less an
allowance for doubtful accounts of $307,000, $360,000, and $460,000 for the
years ended December 31, 1997, 1998, and 1999, respectively. Bad debt
expense for each of the years ended December 31, 1997, 1998, and 1999 was $0,
$206,805, and $242,993, respectively.
Property and Equipment - Property and equipment is stated at cost less
accumulated depreciation and amortization. The cost of property and
equipment is depreciated and amortized over the estimated useful lives of the
related assets, ranging from five to ten years, using the straight-line
method.
Software Development Costs - Costs incurred to establish the technological
feasibility of computer software products are research and development costs
and are charged to expense as incurred. Costs of producing product masters
subsequent to establishing technological feasibility, including coding and
testing, are capitalized. Capitalization of computer software costs ceases
when the product is available for general release to customers. Amortization
of capitalized software development costs for the years ended December 31,
1997, 1998 and 1999 were $1,484,276, $1,756,798, and $2,077,643,
respectively. Accumulated amortization of capitalized software development
costs is $4,829,271, $6,586,069, and $8,663,712 at December 31, 1997, 1998,
and 1999, respectively. Capitalized software development costs are amortized
using either the straight-line method over the estimated economic life of the
products (initially five years) or the ratio of current revenues to current
and anticipated revenues for the product, whichever results in the greater
amount of amortization. Unamortized capitalized costs of a computer software
product in excess of its estimated net realizable value are expensed. No
such expense has been recorded for the years ended December 31, 1997, 1998
and 1999.
Goodwill - Goodwill is stated at cost less accumulated amortization.
Goodwill is amortized using the straight-line method over a period of seven
years. Amortization of goodwill for the years ended December 31, 1997, 1998,
and 1999 was $408,000, $407,549, and $407,549, respectively. Accumulated
goodwill amortization as of December 31, 1997, 1998, and 1999 was $782,556,
$1,189,805, and $1,597,354, respectively. The Company assesses the
recoverability of goodwill based upon projected operations over a period
which represents the approximate remaining life of goodwill. The Company
evaluates the recoverability of goodwill based on this forecast of future
cash from operations and income, and using an undiscounted rate that reflects
the Company's average cost of funds.
37
Revenues - Revenues are derived from the sale of computer hardware, licensing
and sub-licensing of software, professional and technical consulting
services, and maintenance and support services. Each customer contract is
negotiated separately. Application software licenses, other than software
customizations, and computer system equipment revenues are recorded when they
are delivered. Installation and training revenues, which are included with
services and other revenues in the statements of operations, and customized
software revenues are recognized on a percentage-of-completion method based
upon completion of specified milestones. Software support revenues
principally include contracts for continuing support services which cover a
specific period, and from which revenue is recognized ratably over the period
of the contract. Also included in software support revenue are revenues from
other significant continuing obligations and post contract support
obligations, which are typically under separate contract and are recognized
as the services are performed. Other service revenues are recognized as the
services are performed.
Employee Benefit Plan - The Company has a 401(k) defined contribution savings
plan covering all full-time employees. Eligible employees may elect to defer
up to 20% of their compensation, but limited to the maximum allowed by the
Internal Revenue Code. Company contributions are made at the discretion of
the Board of Directors and amounted to $420,487, $349,454, and 304,998 in
1997, 1998 and 1999, respectively. During 1999 the employer match
contribution for 1998 and 1999 were made through the issuance of 208,823 and
194,713 of the Company's common stock, respectively.
Stock-Based Employee Compensation Plans - The Company accounts for its stock
option plan in accordance with the provisions of Accounting Principles Board
("APB") Opinion No. 25, "Accounting for Stock Issued to Employees", and
related interpretations. As such, compensation expense would be recorded on
the date of grant only if the current market price of the underlying stock
exceeded the exercise price. The Company adopted Statement of Financial
Accounting Standards (SFAS) No. 123, "Accounting for Stock-Based
Compensation", which permits entities to recognize as expense over the
vesting period the fair value of all stock-based awards on the date of grant.
Alternatively, SFAS No. 123 allows entities to continue to apply the
provisions of APB Opinion No. 25 and provide pro forma net income and pro
forma earnings per share disclosures for employee stock option as if the
fair-value-based method defined in SFAS No. 123 had been applied. The
Company elected to continue to apply the provisions of APB Opinion No. 25 and
provide the pro forma disclosures of SFAS No. 123 for options issued to
employees.
Income Taxes - Deferred income taxes are provided on items that are
recognized in different reporting periods for financial accounting and income
tax purposes using the then enacted tax rates.
Earnings Per Share - Basic earnings per share is computed on the basis of the
weighted average number of shares outstanding. Diluted earnings per share is
computed on the basis of the weighted average number of shares outstanding
plus potential common stock which would arise from the exercise of stock
options and warrants, if dilutive.
The following is a reconciliation of basic net earnings (loss) per share for
the years ended December 31, 1997, 1998 and 1999:
<TABLE>
1997 1998 1999
<S> <C> <C> <C>
Net earnings (loss) $ 1,042,958 $(9,012,690) $ 854,368
Preferred stock dividends - (67,555) (160,000)
Earnings (loss) available for common
shareholders $ 1,042,958 $ (9,080,245)$ 694,368
Average shares outstanding
-Basic 17,905,214 18,127,641 18,578,573
Diluted effect of options and warrants 526,200 - 295,128
Average shares outstanding
-Diluted 18,431,414 18,127,641 18,873,701
Earnings (loss) per share
-Basic and diluted $ 0.06 $ (0.50)$ 0.04
</TABLE>
38
Cash Equivalents - For purposes of the statement of cash flows, the Company
considers all highly liquid investments purchased with an original maturity
of three months or less to be cash equivalents.
Use of Estimates - The preparation of financial statements in conformity with
generally accepted accounting principles requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date
of the financial statements and the reported amounts of revenues and expenses
during the reporting period. Significant estimates relate to revenue
recognition on contracts and to the recoverability of software development
costs and goodwill. Actual results could differ from those estimates.
Concentration of Credit Risk - The Company generates revenue primarily
through sales to entities operating within the healthcare industry located
throughout the United States. Due to this concentration, substantially all
receivables at December 31, 1998 and 1999, are from healthcare institutions
which may be similarly affected by changes in economic, regulatory or other
conditions. The Company performs ongoing credit evaluations of its customers
and generally does not require collateral. The Company maintains reserves
for potential credit losses and such losses have been within management's
expectations.
The Company invests its excess cash in deposits with major financial
institutions, in U.S. government agency securities and in commercial paper of
companies with strong credit ratings. Generally, the investments mature
within 90 days and, therefore, are subject to little risk. The Company has
not experienced losses related to these investments.
Fair Value of Financial Instruments - The following methods and assumptions
were used to estimate the fair value of the Company's financial instruments:
The fair value of cash and cash equivalents, trade receivables and trade
accounts payable approximate their carrying amounts because of the short
maturity of those instruments. The fair value of contract receivables
approximates its carrying value, and is estimated by discounting the
guaranteed minimum payments and unguaranteed contract residuals at the
imputed incremental borrowing rates of the related customers (see also Note C
herein). The fair value of bank note payable and line of credit are
estimated based on the current rates available to the Company for debt of the
same remaining maturities and approximates its carrying amount.
Segment Information - The Company does not identify separate operating
segments for management reporting purposes. The results of operations are
the basis on which management evaluates operations and makes business
decisions.
Reclassifications - Certain prior year balances have been reclassified to
conform to the 1999 presentation.
B. PROPERTY AND EQUIPMENT
Property and equipment consists of the following:
<TABLE>
December 31,
1998 1999
<S> <C> <C>
Furniture and fixtures $ 1,245,211 $ 1,224,039
Equipment 6,848,943 6,954,570
Leasehold improvements 1,553,173 1,558,386
9,647,327 9,736,995
Less accumulated depreciation and amortization 4,479,891 5,629,514
$ 5,167,436 $ 4,107,481
</TABLE>
C. CONTRACTS RECEIVABLE:
Contracts receivable represent receivables from customers under long-term
financing arrangements.
On July 5, 1997, the Company entered into a multi-site radiology information
system sale payable in varying monthly installments extending through March
2003. Total minimum installments due under this contract aggregate
39
$5,754,000. Deferred revenue equal to the present value of the minimum
payments and estimated residual value discounted at an imputed rate of 8.5%,
of $3,618,000 was initially recorded. During 1997, $3,402,000 of revenue was
recognized upon implementation of the system and $125,000 of interest income
was recognized on the related contract receivable. On November 28, 1997 the
Company assigned its rights to receive minimum payments under this contract
to a third party in exchange for cash.
Also included in contracts receivable are other amounts due from customers in
monthly installments of principal and interest with initial terms ranging
from one to five years. The future minimum principal payments to be received
under contract receivables as of December 31, 1999 are summarized as follows:
<TABLE>
Year Ended December 31,
<C> <C>
2000 $ 155,344
2001 145,403
2002 70,644
2003 439,387
2004 66,974
Thereafter 19,036
Total $ 896,788
</TABLE>
D. LEASE OBLIGATIONS
On September 1, 1998 the Company relocated its corporate headquarters to
Lake Mary, Florida.
Capital Leases
In connection with the Company's relocation, in September of 1998, the
Company leased furniture and fixtures under a capital lease obligation.
The capital lease obligation requires 36 non-cancelable monthly
installments of $15,837 which began in October 1998, bears an interest
rate of 9.8% and provides for a $100 purchase option to the Company at
lease expiration in October 2001. Furniture and fixtures under the
capital lease obligation are summarized as follows, as of December 31,
1998 and 1999:
<TABLE>
1998 1999
<S> <C> <C>
Cost $ 523,049 $ 523,049
Accumulated Depreciation (33,100) (113,569)
Net Book Value December 31, 1999 $ 489,949 $ 409,480
</TABLE>
Minimum future lease payments under the capital lease obligation as of
December 31, 1999 are summarized as follows:
<TABLE>
Year Ended December 31,
<C> <C>
2000 $ 190,044
2001 142,533
332,577
Less: Amount representing interest (28,092)
304,485
Less: Current portion of capital lease obligation (167,585)
Non-current portion of capital lease obligation $ 136,900
</TABLE>
The capital lease obligation balances are included with other current and
non-current liabilities on the balance sheet.
Operating Leases
The Company leases office space under non-cancelable operating leases. The
leases call for monthly payments over terms of 60 to 78 months and include
renewal options. Total rent expense on all operating leases was $1,217,000,
$1,609,000, and $1,445,000 for the years ended December 31, 1997, 1998 and
1999, respectively.
40
The future minimum rental payments under operating leases as of December 31,
1999 are as follows:
<TABLE>
Year Ended December 31,
<C> <C>
2000 $ 1,923,580
2001 2,022,726
2002 2,040,914
2003 2,059,640
2004 1,994,816
Thereafter 183,684
Total $10,225,360
</TABLE>
Deferred Lease Incentives
In connection with the lease of the Lake Mary office space the Company was
provided $1,236,503 of lease incentives, which are being amortized on a
straight line basis over the 78 month lease term beginning September 1, 1998,
as a reduction in office rent expense. During 1999, the Company recognized
$190,230 of deferred lease incentive against office rent expense.
E. NOTE PAYABLE
Included in other current and non-current liabilities is a note payable (the
"Note"). The Note is payable in fixed monthly installments of $7,228, bears
fixed interest at a rate of 8.74%, and matures on February 1, 2003. On
December 31, 1999 current and long-term portions on the Note were $68,536 and
$170,648, respectively.
The Note was issued subject to the terms of the sale of the Company's right
to receive minimum payments under a radiology system contract (the
"Contract") (see also Note C). The Note plus any accrued interest becomes
immediately due should any of the following occur: 1) The Company fails to
make a scheduled installment payment. 2) Any default in the agreement
governing the sale of the minimum payments occurs. 3) The customer defaults
on the terms of the Contract. The Note is secured by all the hardware and
software included in the Contract plus any payments due to the Company under
the Contract other than the minimum payments sold.
As of December 31, 1999, maturities pursuant to the Note are as follows:
<TABLE>
Year Ended December 31,
<C> <C>
2000 $ 68,536
2001 74,772
2002 81,575
2003 14,301
Total $ 239,184
</TABLE>
F. LINE OF CREDIT
On July 24, 1998 the Company entered into a $5,000,000 Revolving Line of
Credit Agreement with Silicon Valley Bank, a commercial bank ("Bank"). The
Revolving Line of Credit Agreement is secured by all existing Company assets
and matures on April 23, 2000. Interest thereon is payable monthly in
arrears at the Bank's prime rate (8.5% on December 31, 1999). Future
borrowing capacity is contingent on the Company's compliance with a minimum
quick ratio (as defined) of 1.25 to 1, and maintaining profitable quarterly
operations in excess of any increase in the carrying value of capitalized
software development costs in 1999, at which time the borrowing capacity will
be limited to the lessor of $5,000,000 or 70% of qualified receivables. As
of December 31, 1999 borrowings against this line of credit were $700,000,
and $156,616 of interest expense on the line of credit had been recognized in
1999.
G. SERIES C REDEEMABLE CONVERTIBLE PREFERRED STOCK
On July 29, 1998 the Company issued 1,000,000 shares of Series C Redeemable
Convertible Preferred Stock ("Series C Preferred Stock") together with
detachable Warrants to purchase an aggregate of 300,000 Common Shares of the
Company in a private placement transaction, which resulted in net proceeds to
41
the Company of $1,814,000. The Series C Preferred Stock is convertible on a
share for share basis to Common Stock, is non-voting, carries a $.16 per
share cumulative annual dividend payable calendar quarterly in arrears, has a
liquidation preference of $2.00 per share, may be automatically converted
upon the Company's Common Stock sustaining sufficient trading at or above
$4.00, and is redeemable by the Company on or after July 29, 2000 at a price
of $2.00 per share. The Warrants are exercisable at $2.25 per Common Share
at any time on or before July 29, 2003. On September 29, 1998 common stock
underlying the Series C Preferred Stock and Warrants ("Securities") was
registered under the Securities Act of 1933, as amended. On December 31,
1998 and December 31, 1999 all of the then accrued Series C Preferred Stock
dividends aggregating $67,555 and $160,000, respectively, were declared and
paid.
H. CAPITAL STOCK, WARRANTS AND OPTIONS
During 1993, the shareholders approved and the Company adopted a stock
warrant and option plan for directors and management employees (the "D&M
Plan"), whereby 250,000 shares of common stock were reserved for issuance.
During 1997, the shareholders approved increasing shares reserved for
issuance pursuant to the D&M Plan to 650,000. Under the D&M Plan directors'
and management employee warrants are five year warrants which vest under
varying terms and are issued at an exercise price equal to the market price
of the Company's common stock on the date of grant. During 1995, the
shareholders approved an amendment to the D&M Plan to conform the terms of
vesting to 40% upon grant plus 20% per year for each of three years
thereafter, and to provide for early vesting upon death or employment
termination without cause for all future options granted under the D&M Plan.
Additionally, annual warrants are issued to certain outside directors at the
beginning of that director's third consecutive term in office. Each annual
warrant is for 5,000 shares of the Company's Common Stock, has a five year
term, has an exercise price equal to the average of the closing bid and ask
prices of the Company's Common Stock on the date of issuance, and is fully
vested upon issuance. At December 31, 1999 the Company had stock warrants
and options outstanding to purchase shares of its common stock under the D&M
Plan as follows:
<TABLE>
Number Presently Price Year Expiration
of Shares Exercisable Per Share Granted Date
Directors'
<S> <C> <C> <C> <C> <C>
Warrants: 5,000 5,000 $1.00 1995 June 2000
5,000 5,000 $1.97 1996 Mar. 2001
76,500 76,500 $6.06 1996 May 2001
10,000 8,000 $5.88 1997 June 2002
8,000 4,800 $1.44 1998 June 2003
20,000 8,000 $2.13 1999 June 2004
Management Employees'
Options: 7,500 7,500 $4.75 1996 Dec. 2001
97,500 58,500 $3.28 1998 Jan. 2003
229,500 173,300
</TABLE>
D&M Plan options activity is summarized as follows:
<TABLE>
Shares
<S> <C>
Options outstanding at December 31, 1996 189,000
Exercised (5,000)
Granted 109,999
Canceled -
Options outstanding at December 31, 1997 293,999
Exercised (25,500)
Granted 133,000
Canceled (96,166)
Options outstanding at December 31, 1998 305,333
Exercised (17,000)
Granted 20,000
Canceled (78,833)
Options Outstanding at December 31, 1999 229,500
</TABLE>
42
The Company adopted an incentive stock option plan in 1983 for key employees
whereby 400,000 shares of common stock were reserved for issuance under the
Plan. Options granted vest 40%, 30% and 30% on the first, second and third
anniversaries of their issuance, respectively and expire ten years after the
date of grant. At December 31, 1999, the Company had granted options of
355,040 shares, of which options for 118,240 shares had been exercised,
233,800 expired unexercised and options for 3,000 shares were exercisable at
a weighted average exercise price of $1.72 per share and a weighted average
remaining contractual life of five months as of December 31, 1999. No new
options will be granted or were granted after December 31, 1992 under the
terms of this Plan.
During 1993, the shareholders approved and the Company adopted a new ten year
incentive stock option plan for employees whereby 100,000 shares of common
stock were reserved for issuance under the Plan. The terms of this 1993 ISO
Plan are similar to the 1983 Plan. During 1995 and 1997, the shareholders
approved increasing shares reserved for issuance pursuant to the 1993 ISO
Plan to 600,000 then 1,500,000, respectively. At December 31, 1999, the
Company had granted options of 2,312,907 shares, 135,650 options had been
exercised, 1,164,633 options were terminated and options for 408,412 shares
were exercisable at a weighted average exercise price of $3.35 and a weighted
average remaining contractual life of 7.0 years. Under both the 1983 Plan
and the 1993 Plan, the exercise price for stock options may not be less than
the market price of the Company's common stock at date of grant. As of
December 31, 1999 options under the 1993 plan are summarized as follows:
<TABLE>
Range of Weighted Average Weighted Average
Exercise Price Outstanding Exercise Price Remaining Contractual Life
<C> <C> <C> <C>
$ .96 - $1.41 174,175 $1.01 8.4 Years
$ 1.56 - $2.28 556,850 1.75 8.9 Years
$ 2.45 - $3.31 63,000 3.28 8.0 Years
$ 4.37 - $5.25 218,599 4.90 7.1 Years
1,012,624 $2.40 8.4 Years
Range of Weighted Average Weighted Average
Exercise Price Outstanding Exercise Price Remaining Contractual Life
$ .96 - $1.41 41,775 $1.00 6.2 Years
$ 1.56 - $2.28 147,380 1.97 7.0 Years
$ 2.45 - $3.31 27,000 3.26 7.9 Years
$ 4.37 - $5.25 192,257 4.94 7.1 Years
408,412 $3.35 7.0 Years
</TABLE>
As of January 1, 1999 and December 31, 1999, the weighted average exercise
prices of options outstanding under the ISO Plans were $2.72 and $2.39,
respectively. Additionally, during 1999 the weighted average exercise prices
of options exercised, granted and canceled under the ISO Plans were $1.00,
$1.39 and $2.17, respectively.
43
Incentive stock option activity under the 1983 and 1993 Plans and price
information follows:
<TABLE>
Stock Option
Shares Price Range
<S> <C> <C>
Options outstanding at December 31, 1996 576,840 $1.00 - $5.38
Exercised (51,940) $1.00 - $1.97
Granted 397,707 $3.59 - $5.19
Canceled (61,360) $1.00 - $5.00
Options outstanding at December 31, 1997 861,247 $1.00 - $5.38
Exercised (1,650) $1.00 - $1.97
Granted 757,750 $ .97 - $3.28
Canceled (579,019) $1.00 - $5.38
Options outstanding at December 31, 1998 1,038,328 $ .97 - $5.25
Exercised (60,650) $1.00 - $1.00
Granted 522,200 $1.00 - $2.20
Canceled (484,254) $1.00 - $5.25
Options outstanding at December 31, 1999 1,015,624 $ .97 - $5.25
</TABLE>
During 1993 the shareholders approved and the Company adopted an Employee
Stock Purchase Plan effective for a five year period beginning January 1,
1994. The Company reserved 200,000 shares of common stock for issuance under
the Plan. During 1997, the shareholders approved increasing shares reserved
for issuance to 600,000 shares, and during 1998 shareholders approved
extending the Plan through December 31, 2003. The Plan operates in one or
more phases of six months each and is open for enrollment by employees
working at least 20 hours per week and who have completed at least five
months of service. A summary of plan activity is as follows:
<TABLE>
Phase # Phase Ending Date Shares Issued Price
<C> <C> <C> <C>
1 June 30, 1994 5,274 $ 1.650
2 December 31, 1994 2,535 $ .980
3 June 30, 1995 6,256 $ .930
4 December 31, 1995 22,575 $ .930
5 June 30, 1996 14,026 $ 2.045
6 December 31, 1996 17,321 $ 4.202
7 June 30, 1997 23,826 $ 4.200
8 December 31, 1997 40,116 $ 3.010
9 June 30, 1998 50,964 $ 1.590
10 December 31, 1998 57,973 $ .680
11 June 30, 1999 70,014 $ .630
12 December 31, 1999 24,543 $ 1.430
</TABLE>
Phase ten (10) and twelve (12) shares were issued in January 1999 and
2000, respectively.
The Company's Board of Directors, in connection with employment agreements,
has granted employment options. Employment options are exercisable for five
years from the date of grant in accordance with a vesting schedule of 40%
upon grant plus 20% per year for each of three years thereafter at an
exercise price equal to the fair market value on the date of the grant. On
August 23, 1994, the Company's Board of Directors, in connection with an
employment agreement, granted options to Mitchel J. Laskey, the Company's
President and then COO (now CEO), for 250,000 shares of common stock under
similar terms at an exercise price equal to the fair market value on the date
of the grant of $1.6875. On September 13, 1995, the Company's Board of
Directors reduced the exercise price on Mr. Laskey's employment options to
$1.00 per share. On December 17, 1996 the Company's Board of Directors, in
44
connection with various other employment agreements, granted options covering
96,000 shares of common stock under similar terms at an exercise price equal
to fair market value on the date of the grant of $5.00. On January 1, 1997
the Company's Board of Directors granted additional employment options to
Mitchel J. Laskey for 50,000 shares of common stock under similar terms at an
exercise price of $4.63 which represents the fair market value on the date of
grant. During 1998 47,500 of the Mitchel J. Laskey January 1, 1997 options
expired. On January 1, 1998 the Company's Board of Directors approved
additional options to Mitchel J. Laskey for 400,000 shares of common stock,
100,000 shares at a strike price of $6.00, $7.50, $9.00 and $10.50 each. All
of these employment option agreements provide for early vesting upon death or
employment termination without cause and were issued at exercise prices no
less than the fair market value of the shares on the date of grant. As such,
in accordance with APB 25 no corresponding compensation expense was
recognized.
The Articles of Incorporation authorize 20,000,000 shares of $.01 par value
common stock. During 1997, the Company's shareholders approved increasing
the number of authorized common shares to 40,000,000.
The Articles of Incorporation authorize 10,000,000 shares of $.01 par value
preferred stock, in such series and variations in the relative rights and
preferences, including voting rights, if any, between series as the Board of
Directors shall determine.
On July 31, 1995 the Company completed a Private Placement Offering issuing
$775,000 of Subordinated Convertible Notes, bearing simple interest at 9% per
annum, together with detachable warrants to purchase 155,000 shares of the
Company's common stock, ("debt warrants"). The warrants are exercisable at
$1.00 per common share, and are exercisable for five years from the date of
issuance (70,000 in June 1995 and 85,000 in July 1995). On November 28,1995
all of the Subordinated Convertible Notes were converted into 968,750 shares
of Series A Preferred Stock. As of December 31, 1999, 30,000 of the debt
warrants were exercised.
In connection with the Private Placement of the shares of Series B Preferred
Stock, the Board of Directors of the Company authorized the issuance on
December 8,1995 of warrants to purchase 210,000 shares of the Company's
common stock for $1.00 per share to a financial consultant ("Series B
warrants") for $25,000. These warrants are exercisable for five years from
the date of issuance. As of December 31, 1998, none of the Series B warrants
were exercised.
On December 17, 1996, in connection with the acquisition of CoMed, the
Company issued 1,000,000 common shares and 6,000 shares of Series CM
Preferred Stock, $.01 par value, to the former shareholders of CMSI. The
Series CM Preferred Stock was automatically converted into 564,996 shares of
the Registrant's common stock at the close of business on August 29, 1997
("Contingent Shares"), pursuant to a formula based upon the average closing
bid and ask price of the Registrants common stock as quoted on the National
Market for the five (5) trading day period ending August 29, 1997 (the
"CSAVG"). The CSAVG during this period was $5.175 and the number of shares
of the Registrant's common stock issued as Contingent Shares was pro-rated
accordingly.
During 1998 the employer match contribution of $349,454 to the Company's
401(k) defined contribution savings plan was made through the issuance of
208,823 shares of the Company's common stock at an average price of $1.67 per
share. During 1999 the employer match contribution of $304,998 to the
Company's 401(k) defined contribution savings plan was made through the
issuance of 194,713 shares of the Company's common stock at an average price
of $1.57 per share.
45
I. REALIGNMENT COSTS
During the third quarter of 1999 the Company announced a realignment plan.
This realignment was designed to provide a single focus to the development,
marketing, sales and support of the Company's information systems. It also
established specific cost reductions, revenue improvement and customer
satisfaction objectives and anticipated future cost efficiencies. In
connection with the plan, a total of seventeen employees were terminated.
Termination benefits as of and for the year ended December 31, 1999 are
summarized as follows:
<TABLE>
# of
Terminated Benefits Benefits Total
Department Employees Paid Accrued Realignment Costs
<S> <C> <C> <C> <C>
Client Services 6 $ 27,374 $ 994 $ 28,368
Software Development 6 55,114 -- 55,114
Sales and Marketing 4 192,043 -- 192,043
General and Administrative 1 239,611 8,433 248,044
17 $514,142 $9,427 $523,569
</TABLE>
J. INCOME TAXES
The components of income tax expense (benefit) are as follows:
<TABLE>
Year Ended December 31,
1997 1998 1999
Current income tax expense (benefit)
<S> <C> <C> <C>
before operating loss carry forward $ -- $ -- $342,000
Tax effects of temporary differences, net of
Changes in related valuation allowance 725,000 431,000 200,000
Benefits of operating loss carry forward (725,000) (431,000)(542,000)
$ -- $ -- $ --
</TABLE>
Deferred income taxes reflect the net tax effects of operating loss and tax
credit carryforwards and temporary differences between the carrying amounts
of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes. The tax effects of significant items
comprising the Company's net deferred tax as of December 31, 1998 and 1999,
are as follows:
<TABLE>
1998 1999
Deferred tax asset:
<S> <C> <C>
Net operating loss carryforwards $ 8,488,000 $ 7,753,000
Tax credit carryforwards 655,000 551,000
Other 458,000 528,000
9,601,000 8,832,000
Deferred tax liabilities:
Capitalized software development costs (3,120,000) (3,128,000)
Other (60,000) (235,000)
Net deferred tax asset 6,421,000 5,469,000
Valuation allowance (6,421,000) (5,469,000)
Net deferred tax $ -- $ --
</TABLE>
The net deferred tax asset is reduced by a valuation allowance due to the
uncertainty associated with the realization of the net deferred tax asset.
The valuation allowance decreased $952,000 from the allowance of $6,421,000 at
December 31, 1998.
The provisions for Federal income taxes differs from the amount computed by
applying the statutory rate to net earnings (loss) before income taxes for
each of the three years in the period ended December 31, 1999 as follows:
46
<TABLE>
Amount of Tax
1997 1998 1999
<S> <C> <C> <C>
Computed expected tax expense (benefit) $ 355,000 $(3,154,000) $ 299,000
State taxes, net of federal benefit -- (450,000) 43,000
Non-recognition (recognition) of the
benefits of operating loss
carryforward and the related
valuation allowance change (355,000) 3,604,000 (342,000)
$ -- $ -- $ --
</TABLE>
At December 31, 1999, the Company had unused net operating loss carryforwards
for tax and alternative minimum tax purposes of approximately $19,383,000 and
$18,772,000, respectively, and unused tax credits of approximately $551,000.
These operating loss carryforwards and tax credits expire in varying amounts
during 2000 through 2013.
K. RELATED PARTY TRANSACTIONS
The Company expensed $159,000, $63,000, and $46,500 during 1997, 1998 and
1999, respectively, for consulting and advisory fees paid to MMRI, Inc. which
is majority owned by the Company's former Chairman of the Board, David
Pomerance.
The private placement transaction closing on July 29, 1998, more fully
discussed in Note G, was solely subscribed to by executive officers and
directors of the Company on terms negotiated by non-participating directors
and executive officers with the Company's investment banker.
L. LITIGATION
In July 1997, the Company commenced a declaratory judgement action in Dakota
County, Minnesota District Court seeking a declaration that the Company had
properly terminated the services of an individual. The individual filed a
counterclaim and demanded $200,000 in settlement of a claim alleging breach
of contract, promissory estoppel and fraud. On October 22, 1999 judgement
was entered in favor of the Company.
As of the date hereof, there are no other material legal proceedings pending
against the Company. In the opinion of management, the legal proceedings in
which the Company is involved will not have a material effect on the
Company's consolidated financial statements.
M. STOCK BASED COMPENSATION PRO FORMA INFORMATION
Options granted to the Company's directors and employees under the 1983 and
1993 Incentive Stock Option Plans, various employment agreements, and the D&M
Stock Option Plan (hereafter, the "Plans"), are accounted for under APB
Opinion 25, Accounting for Stock Issued to Employees, and related
interpretations. The exercise price of each option granted under these Plans
is at least equal to the market price of the Company's stock on the date of
grant. Accordingly, no compensation has been recognized for directors and
employees under these Plans. Had compensation cost for the Plans been
determined based on the fair value of the options at the grant dates
consistent with the method of Statement of Financial Accounting Standards 123,
Accounting for Stock-Based Compensation (SFAS 123), the Company's net
earnings (loss) and net earnings (loss) per share would have reflected the
pro forma amounts indicated below.
<TABLE>
1997 1998 1999
<S> <S> <C> <C> <C>
Net earnings (loss) As reported $1,042,958 $(9,012,690) $854,368
Pro forma $ 173,536 $(9,448,792) $442,200
Net earnings (loss) available As reported $1,042,958 $(9,080,245) $694,368
to common shareholders Pro forma $ 173,536 $(9,516,348) $282,200
Basic and diluted earnings As reported $ .06 $(0.50) $.04
(loss) per share Pro forma $ .01 $(0.52) $.01
</TABLE>
47
The fair value of each option grant under SFAS 123 is estimated on the date
of grant using the Black-Scholes option-pricing model assuming no future common
stock dividend declarations. Volatility was computed based on the
daily common stock high, low and close information provided by NASDAQ for the
twenty days prior to the close of trading on the date of each option grant,
and range from 61% - 114% for options granted during 1997, 59% - 234% for
options granted during 1998, and 116% - 331% for options granted during 1999.
Risk free rates of 6.5% for options granted with a ten year exercise period,
and 6% for options granted with a three to five year exercise period were
used for options granted during 1997 and 5% for all options granted during
1998 and 1999. The initial forfeiture rate under the 1993 ISO Plan for 1997
was 30%, for 1998 was 70%, and for 1999 was 44%. Under the D&M Plan, the
initial forfeiture rate for 1997 was 15%, and ranged between 0% and 15% for
options granted in connection with continuing employment agreements. The
initial forfeiture rate under the D&M Plan for 1998 and 1999 was 35% and for
options granted in connection with employment agreements was 100%. The
weighted average grant date fair value of options granted during 1997, 1998,
and 1999 were $2.23 and $0.41, and $.71, respectively.
N. UNAUDITED QUARTERLY INFORMATION
Quarterly operating results are summarized as follows (in thousands, except
per share data):
<TABLE>
Three Months Ended (Unaudited)
1998 March 31 June 30 September 30 December 31
<S> <C> <C> <C> <C>
Total Operating Revenues $ 6,034 $ 6,327 $ 8,319 $ 5,149
Operating Income (Loss) (3,015) (2,252) (9) (3,777)
Net Earnings (Loss) (2,919) (2,199) (100) (3,795)
Net Earnings (Loss) Per Share (.16) (.12) (.01) (.21)
Shareholders' Equity 18,557 16,628 18,410 14,626
Three Months Ended (Unaudited)
1999 March 31 June 30 September 30 December 31
Total Operating Revenues $ 9,843 $ 9,925 $ 7,502 $ 7,873
Operating Income (Loss) 479 609 (201) 169
Net Earnings (Loss) 438 549 (266) 133
Net Earnings (Loss) Per Share .02 .03 (.02) .01
Shareholders' Equity 15,150 15,765 15,763 15,921
</TABLE>
48
INDEPENDENT AUDITORS' REPORT
To the Board of Directors
Dynamic Healthcare Technologies, Inc.
We have audited the accompanying balance sheet of Dynamic Healthcare
Technologies, Inc. as of December 31, 1999 and the related statements of
operations, shareholders' equity and cash flows for the year then ended.
These financial statements are the responsibility of the company's
management. Our responsibility is to express an opinion on these financial
statements based on our audit.
We conducted our audit in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements.
An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audit provides a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Dynamic Healthcare
Technologies, Inc. at December 31, 1999, and the results of its operations
and its cash flows for the year then ended in conformity with generally
accepted accounting principles.
/S/BDO SEIDMAN, LLP
BDO SEIDMAN, LLP
Orlando, Florida
February 11, 2000
49
INDEPENDENT AUDITORS' REPORT
To the Board of Directors
Dynamic Healthcare Technologies, Inc.
We have audited the accompanying consolidated balance sheets of Dynamic
Healthcare Technologies, Inc. as of December 31, 1997 and 1998, and the
related statements of operations, shareholders' equity, and cash flows for
the years then ended. These consolidated financial statements are the
responsibility of the company's management. Our responsibility is to express
an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements.
An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the financial position of Dynamic
Healthcare Technologies, Inc. as of December 31, 1997 and 1998, and the
results of their operations and their cash flows for the years then ended in
conformity with generally accepted accounting principles.
/S/KPMG LLP
KPMG LLP
Orlando, Florida
February 19, 1999
51
CORPORATE INFORMATION
Board of Directors
Jerry L. Carson Mitchel J. Laskey, C.P.A.
Executive Vice President and Chief President and Chief Executive Officer
Financial Officer Dynamic Healthcare Technologies, Inc.
Evans Enterprises
Bret R. Maxwell Thomas J. Martinson
Co-Chairman President
First Analysis Martinson & Company, Ltd.
Daniel Raynor
Managing Partner
The Argentum Group
Executive Officers
Mitchel J. Laskey Paul S. Glover
President and Chief Executive Officer Vice President, Finance
Treasurer Chief Financial Officer and Secretary
Corporate Officers
Steven J. Akerson Michael A. Pomerance
Vice President and General Manager Vice President and General Manager
Lab and Imaging Radiology
John P. Fingado Joseph M. Johnson
Vice President and General Manager Area Vice President, Pathology Sales
Pathology
Mary Lu Lander Michael Karnes
Vice President, Corporate Marketing Area Vice President, Radiology Sales
and Services
Brian M. Paige
Vice President and General Manager
Development and Tools Group
Legal Counsel
Cohen, Berke, Bernstein, Brodie & Kondell, P.A.
2601 S. Bayshore Drive
Miami, Florida 33133-5460
(305)854-5900
Transfer Agent Independent Auditors
Norwest Bank Minnesota, N.A. BDO Seidman, LLP
161 North Concord Exchange 201 South Orange Avenue, Suite 950
St. Paul, Minnesota 55075 Orlando, Florida 32801
(612)450-4064 (407) 841-6930
51
STOCK TRADING INFORMATION
The Common Stock of Dynamic Healthcare Technologies, Inc. is traded on the
NASDAQ National Market System under the NASDAQ symbol DHTI.
COMMON STOCK INFORMATION
The number of stockholders of record of the Company's Common Stock was
approximately 3,685 on March 10, 1998. High and low bid quotations for the
Common Stock for the last eight quarters are presented below:
<TABLE>
1998 1999
Quarter Ended High Low High Low
<S> <C> <C> <C> <C>
March 31 $3.7500 $2.2500 $2.125 $ .625
June 30 2.5630 0.8750 2.750 1.813
September 30 2.3750 0.9380 2.563 1.188
December 31 1.1880 0.4690 1.875 1.125
</TABLE>
The foregoing quotations reflect inter-dealer prices without retail mark-up,
mark-down, or commission and may not necessarily represent actual
transactions.
ANNUAL REPORT ON FORM 10-K, WITHOUT EXHIBITS
Dynamic Healthcare Technologies, Inc.'s annual filing with the Securities and
Exchange Commission (Form 10-K) is available upon request without charge to
shareholders by writing to:
Pamela T. Durkin
Investor Services Department
Dynamic Healthcare Technologies, Inc.
615 Crescent Executive Court
Lake Mary, Florida 32746
[email protected]
(407) 333-5300
ANNUAL MEETING
The Annual Meeting of Shareholders of Dynamic Healthcare Technologies, Inc.
will be held on June 8, 2000, in Lake Mary, Florida.
52
INDEPENDENT AUDITORS' CONSENT
The Board of Directors
Dynamic Healthcare Technologies, Inc.:
We hereby consent to the incorporation by reference in the registration
statements (No. 33-72684, 33-72764 and 333-57713) on Form S-8 of our report
dated February 11, 2000, relating to the financial statements of Dynamic
Healthcare Technologies, Inc. appearing in the Company's Annual Report on
Form 10-K for the year ended December 31, 1999.
/S/BDO SEIDMAN, LLP
BDO SEIDMAN, LLP
Orlando, Florida
February 11, 2000
53
INDEPENDENT AUDITORS' CONSENT
The Board of Directors
Dynamic Healthcare Technologies, Inc.:
We consent to incorporation by reference in the registration statements (No.
33-72684, 33-72764 and 333-57713) on Form S-8 of Dynamic Healthcare
Technologies, Inc. of our reports dated February 19, 1999, relating to the
consolidated balance sheets of Dynamic Healthcare Technologies, Inc. as of
December 31, 1997 and 1998, and the related consolidated statements of
operations, shareholders' equity and cash flows for the years then ended, and
related schedule, which reports appear in the December 31, 1999 report on
Form 10-K of Dynamic Healthcare Technologies, Inc.
/S/KPMG LLP
KPMG LLP
Orlando, Florida
March 8, 2000
54
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-END> DEC-31-1999
<CASH> 1,818,209
<SECURITIES> 0
<RECEIVABLES> 9,050,202
<ALLOWANCES> 459,761
<INVENTORY> 0
<CURRENT-ASSETS> 14,271,119
<PP&E> 9,736,994
<DEPRECIATION> 5,629,513
<TOTAL-ASSETS> 29,659,925
<CURRENT-LIABILITIES> 12,193,491
<BONDS> 307,547
0
1,811,327
<COMMON> 188,419
<OTHER-SE> 13,918,788
<TOTAL-LIABILITY-AND-EQUITY> 29,659,925
<SALES> 4,296,500
<TOTAL-REVENUES> 35,143,400
<CGS> 6,237,188
<TOTAL-COSTS> 34,086,977
<OTHER-EXPENSES> 25,940
<LOSS-PROVISION> 242,993
<INTEREST-EXPENSE> 277,075
<INCOME-PRETAX> 854,368
<INCOME-TAX> 0
<INCOME-CONTINUING> 854,368
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 854,368
<EPS-BASIC> 0.04
<EPS-DILUTED> 0.04
</TABLE>
